Recent Additions

This page includes the documents that were newly added to the repository within the last 30 days.

All these words:

This exact word or phrase:

Any of these words:

None of these words:

Language:

Visit our Help Page for additional assistance

Select a Range:

Select a Format:

Custom Search Builder:

Custom Search Box

Visit our Help Page for additional assistance

Showing 1301 - 1320 of 1994 results

Double Burden of Malnutrition in Guatemala: Co-existence of Childhood Stunting and Overweight and Obesity Within the Household.

Wolf, Maren ;

Mazariegos, Mónica

October 2025 | European Journal of Clinical Nutrition, 2025, v. 79, no. 10

This paper defines the double burden of malnutrition as occurring when over- and undernutrition coexist within a household. It is most common in countries undergoing the nutrition transition where cheap and accessible food is often of poor quality. This brief narrative review examines four cycles of reports from the Epidemiological Health and Nutri ...

10/09/2026

Supporting Files

Title : Double Burden of Malnutrition in Guatemala: Co-existence of Childhood Stunting and Overweight and Obesity Within the Household. Personal Author(s) : Wolf, Maren;Mazariegos, Mónica;Cordón, Oscar;Mesarina, Karla;Jefferds, Maria Elena D.;Addo, O Yaw;Palmieri, Mireya; Published Date : October 2025 Pages in Document : 1066-1068 (6 pdf pages) Source : European Journal of Clinical Nutrition, 2025, v. 79, no. 10 DOI : https://doi.org/10.1038/s41430-025-01638-6 Journal Title : European Journal of Clinical Nutrition
Wolf, M., Mazariegos, M., Cordón, O., Mesarina, K., Jefferds, M. E. D., Addo, O. Y., & Palmieri, M. (2025). Double Burden of Malnutrition in Guatemala: Co-existence of Childhood Stunting and Overweight and Obesity Within the Household. European Journal of Clinical Nutrition, 79(10). https://doi.org/10.1038/s41430-025-01638-6

Wolf, Maren, Mónica Mazariegos, Oscar Cordón, Karla Mesarina, Maria Elena D. Jefferds, O Yaw Addo, and Mireya Palmieri. "Double Burden of Malnutrition in Guatemala: Co-existence of Childhood Stunting and Overweight and Obesity Within the Household." European Journal of Clinical Nutrition 79, no. 10 (2025). https://doi.org/10.1038/s41430-025-01638-6.

Wolf, Maren, et al. "Double Burden of Malnutrition in Guatemala: Co-existence of Childhood Stunting and Overweight and Obesity Within the Household." European Journal of Clinical Nutrition, vol. 79, no. 10, 2025. Stacks. https://doi.org/10.1038/s41430-025-01638-6.
Export RIS Citation Information. TY - Journal Article AU - Wolf, Maren AU - Mazariegos, Mónica AU - Cordón, Oscar AU - Mesarina, Karla AU - Jefferds, Maria Elena D. AU - Addo, O Yaw AU - Palmieri, Mireya AB - This paper defines the double burden of malnutrition as occurring when over- and undernutrition coexist within a household. It is most common in countries undergoing the nutrition transition where cheap and accessible food is often of poor quality. This brief narrative review examines four cycles of reports from the Epidemiological Health and Nutrition Surveillance System (SIVESNU, Spanish acronym) in Guatemala between 2015-2018/19, examining the following indicators: overall double burden of stunting among children aged ≤59 months and overweight or obesity among women aged 15-49 years in the same household, and individual stunting, overweight, and obesity by indigenous/non-indigenous ethnicity. The review also incorporates double burden prevalence in Guatemala from the literature since 1995. In 1995, the double burden prevalence was 13.4%, and negligible change occurred from 2000 to 2018/19 (18.2% and 17.6%, respectively). Individual level prevalences for stunting, overweight, and obesity were notable, with large disparities in stunting prevalence by ethnicity. AB - Author manuscript AN - cdc:261239 C4 - PMC12717790 DO - https://doi.org/10.1038/s41430-025-01638-6 IS - 10 J2 - European Journal of Clinical Nutrition KW - Adolescent KW - Malnutrition KW - Female KW - Nutrition Surveys KW - Pediatric Obesity KW - Family Characteristics KW - Overweight KW - Young Adult KW - Child KW - Growth Disorders KW - Obesity KW - Infant KW - Prevalence KW - Male KW - Middle Aged KW - Humans KW - Child, Preschool KW - Adult KW - Humans KW - Growth Disorders KW - Adolescent KW - Child, Preschool KW - Prevalence KW - Adult KW - Female KW - Malnutrition KW - Overweight KW - Male KW - Young Adult KW - Middle Aged KW - Infant KW - Family Characteristics KW - Child KW - Pediatric Obesity KW - Obesity KW - Nutrition Surveys LA - eng PY - 2025 T2 - European Journal of Clinical Nutrition T2 - European Journal of Clinical Nutrition, 2025, v. 79, no. 10 TI - Double Burden of Malnutrition in Guatemala: Co-existence of Childhood Stunting and Overweight and Obesity Within the Household. VL - 79 UR - https://stacks.cdc.gov/view/cdc/261239 ER -
Contraceptive Use Among Women With Inflammatory Bowel Disease: an Updated Systematic Review.

Zapata, Lauren B. ;

Snyder, Emily M.

November 2025 | Contraception, 2025, v. 151

Hormonal contraceptive use by women with inflammatory bowel disease (IBD) might affect risk of adverse outcomes or contraceptive effectiveness. Our objective was to update a previous systematic review on the safety and effectiveness of contraceptive use among women with IBD.We searched multiple databases from inception through July 15, 2024 for art ...

10/09/2026

Supporting Files

Title : Contraceptive Use Among Women With Inflammatory Bowel Disease: an Updated Systematic Review. Personal Author(s) : Zapata, Lauren B.;Snyder, Emily M.;Tepper, Naomi K.;Curtis, Kathryn M.; Published Date : November 2025 Pages in Document : 111038 (24 pdf pages) Source : Contraception, 2025, v. 151 DOI : https://doi.org/10.1016/j.contraception.2025.111038 Journal Title : Contraception
Zapata, L. B., Snyder, E. M., Tepper, N. K., & Curtis, K. M. (2025). Contraceptive Use Among Women With Inflammatory Bowel Disease: an Updated Systematic Review. Contraception, 151. https://doi.org/10.1016/j.contraception.2025.111038

Zapata, Lauren B., Emily M. Snyder, Naomi K. Tepper, and Kathryn M. Curtis. "Contraceptive Use Among Women With Inflammatory Bowel Disease: an Updated Systematic Review." Contraception 151 (2025). https://doi.org/10.1016/j.contraception.2025.111038.

Zapata, Lauren B., et al. "Contraceptive Use Among Women With Inflammatory Bowel Disease: an Updated Systematic Review." Contraception, vol. 151, 2025. Stacks. https://doi.org/10.1016/j.contraception.2025.111038.
Export RIS Citation Information. TY - Journal Article AU - Zapata, Lauren B. AU - Snyder, Emily M. AU - Tepper, Naomi K. AU - Curtis, Kathryn M. AB - Hormonal contraceptive use by women with inflammatory bowel disease (IBD) might affect risk of adverse outcomes or contraceptive effectiveness. Our objective was to update a previous systematic review on the safety and effectiveness of contraceptive use among women with IBD. AB - We searched multiple databases from inception through July 15, 2024 for articles on contraception and IBD. Outcomes were IBD disease activity or relapse, other adverse health outcomes, and oral contraceptive (OC) effectiveness. We assessed risk of bias for each study and certainty of evidence for most outcomes. AB - Fifteen articles met our inclusion criteria; eight were new. Twelve had high risk of bias and three moderate risk. One cohort study found lower odds of IBD symptoms among hormonal contraceptive users compared with non-hormonal users, but higher odds of intestinal inflammation over 1 year. Nine cohort studies found inconsistent results regarding OC use and disease activity or relapse, with increased and decreased associations; most were not statistically significant. Two cohort studies found no statistically significant associations between OC use and venous thromboembolism (VTE) among IBD patients. One study found no statistically significant association between OC use and abnormal cervical smears. Two pharmacokinetic studies suggested no differences in plasma concentrations of steroid hormones after oral ingestion among participants with and without IBD. We found no evidence examining risk of osteoporosis or osteopenia among women with IBD using contraception. AB - Limited evidence suggested inconsistent findings for increased risk of disease activity or relapse among women with IBD using hormonal contraception (very low certainty of evidence), no differences in other adverse events (very low certainty of evidence), and no differences in contraceptive hormone concentrations. AB - This updated review expands upon the previous review with eight newly identified studies. However, evidence is still limited in quantity and quality, with inconsistent findings on risk of disease activity or relapse and lack of high-quality evidence on risk of VTE and contraceptive effectiveness. Information in this review may be used by guideline development groups that publish evidence-based contraception guidance for clinicians and patients. Further research can focus on these gaps to provide information needed by women with IBD as they make contraceptive choices. AB - Author manuscript AN - cdc:261238 C4 - PMC12404129 DO - https://doi.org/10.1016/j.contraception.2025.111038 J2 - Contraception KW - Female KW - Contraceptive Effectiveness KW - Contraceptives, Oral, Hormonal KW - Humans KW - Contraceptives, Oral KW - Inflammatory Bowel Diseases KW - Contraception KW - contraception KW - inflammatory bowel disease KW - relapse KW - venous thromboembolism KW - contraceptive effectiveness KW - systematic review KW - Humans KW - Female KW - Inflammatory Bowel Diseases KW - Contraceptives, Oral, Hormonal KW - Contraception KW - Contraceptives, Oral KW - Contraceptive Effectiveness LA - eng PY - 2025 T2 - Contraception T2 - Contraception, 2025, v. 151 TI - Contraceptive Use Among Women With Inflammatory Bowel Disease: an Updated Systematic Review. VL - 151 UR - https://stacks.cdc.gov/view/cdc/261238 ER -
Doxycycline Postexposure Prophylaxis is Effective and Highly Acceptable in An Urban Public Sexually Transmitted Disease Clinic: Philadelphia, 2019-2023.

Lewis, Felicia M. T. ;

Cope, Anna B.

December 2025 | Sexually Transmitted Diseases, 2025, v. 52, no. 12

We sought to determine real-world effectiveness of doxycycline postexposure prophylaxis (doxy PEP) in reducing sexually transmitted infections (STIs) among men who have sex with men attending an HIV preexposure prophylaxis (HIV PrEP) clinic in Philadelphia.Data from eligible HIV PrEP patients who did and did not receive doxy PEP from September 1, 2 ...

10/09/2026

Supporting Files

Title : Doxycycline Postexposure Prophylaxis is Effective and Highly Acceptable in An Urban Public Sexually Transmitted Disease Clinic: Philadelphia, 2019-2023. Personal Author(s) : Lewis, Felicia M. T.;Cope, Anna B.;Clark, Kelly;Madera, Robbie;Asbel, Lenore;Newman, Daniel R.;Davis, Nicole L.; Published Date : December 2025 Pages in Document : 734-738 (13 pdf pages) Source : Sexually Transmitted Diseases, 2025, v. 52, no. 12 DOI : https://doi.org/10.1097/OLQ.0000000000002224 Journal Title : Sexually Transmitted Diseases
Lewis, F. M. T., Cope, A. B., Clark, K., Madera, R., Asbel, L., Newman, D. R., & Davis, N. L. (2025). Doxycycline Postexposure Prophylaxis is Effective and Highly Acceptable in An Urban Public Sexually Transmitted Disease Clinic: Philadelphia, 2019-2023. Sexually Transmitted Diseases, 52(12). https://doi.org/10.1097/OLQ.0000000000002224

Lewis, Felicia M. T., Anna B. Cope, Kelly Clark, Robbie Madera, Lenore Asbel, Daniel R. Newman, and Nicole L. Davis. "Doxycycline Postexposure Prophylaxis is Effective and Highly Acceptable in An Urban Public Sexually Transmitted Disease Clinic: Philadelphia, 2019-2023." Sexually Transmitted Diseases 52, no. 12 (2025). https://doi.org/10.1097/OLQ.0000000000002224.

Lewis, Felicia M. T., et al. "Doxycycline Postexposure Prophylaxis is Effective and Highly Acceptable in An Urban Public Sexually Transmitted Disease Clinic: Philadelphia, 2019-2023." Sexually Transmitted Diseases, vol. 52, no. 12, 2025. Stacks. https://doi.org/10.1097/OLQ.0000000000002224.
Export RIS Citation Information. TY - Journal Article AU - Lewis, Felicia M. T. AU - Cope, Anna B. AU - Clark, Kelly AU - Madera, Robbie AU - Asbel, Lenore AU - Newman, Daniel R. AU - Davis, Nicole L. AB - We sought to determine real-world effectiveness of doxycycline postexposure prophylaxis (doxy PEP) in reducing sexually transmitted infections (STIs) among men who have sex with men attending an HIV preexposure prophylaxis (HIV PrEP) clinic in Philadelphia. AB - Data from eligible HIV PrEP patients who did and did not receive doxy PEP from September 1, 2019, to December 31, 2023, were analyzed. We used a cohort study design and Cox models to estimate the associations between doxy PEP receipt and incident gonorrhea (GC), chlamydia (CT), and/or syphilis. We also used a crossover design and Poisson models to estimate incidence rate ratios (IRRs) for any STI and each STI separately among individuals in the year before and after doxy PEP initiation. AB - Among the 508 eligible men, most were young men of color, and 416 (82%) opted to receive doxy PEP. Receiving doxy PEP was associated with a reduction in any incident STI (hazard ratio, 0.61; 95% confidence interval [CI], 0.40-0.93) and any incident CT (hazard ratio, 0.40; 95% CI, 0.21-0.78). Participants experienced a 62% relative reduction in STI rates while taking doxy PEP (IRR, 0.38; 95% CI, 0.29-0.50), including a reduction in CT (IRR, 0.28; 95% CI, 0.20-0.39) and GC (IRR, 0.49; 95% CI, 0.37-0.65). AB - We observed a significant reduction in any STI and CT in both analytic arms, suggesting that doxy PEP is effective in real-world settings. Enhancing doxy PEP implementation would likely reduce community STI transmission. AB - Author manuscript AN - cdc:261237 C4 - PMC12313191 DO - https://doi.org/10.1097/OLQ.0000000000002224 IS - 12 J2 - Sexually Transmitted Diseases KW - Gonorrhea KW - Ambulatory Care Facilities KW - Chlamydia Infections KW - Sexually Transmitted Diseases KW - Young Adult KW - Doxycycline KW - Homosexuality, Male KW - Pre-Exposure Prophylaxis KW - Syphilis KW - Cohort Studies KW - Incidence KW - Post-Exposure Prophylaxis KW - Urban Population KW - Male KW - Middle Aged KW - Humans KW - Anti-Bacterial Agents KW - Adult KW - HIV Infections KW - Humans KW - Male KW - Doxycycline KW - Post-Exposure Prophylaxis KW - Adult KW - Sexually Transmitted Diseases KW - Anti-Bacterial Agents KW - Gonorrhea KW - Homosexuality, Male KW - HIV Infections KW - Chlamydia Infections KW - Young Adult KW - Syphilis KW - Ambulatory Care Facilities KW - Pre-Exposure Prophylaxis KW - Cohort Studies KW - Urban Population KW - Incidence KW - Middle Aged LA - eng PY - 2025 T2 - Sexually Transmitted Diseases T2 - Sexually Transmitted Diseases, 2025, v. 52, no. 12 TI - Doxycycline Postexposure Prophylaxis is Effective and Highly Acceptable in An Urban Public Sexually Transmitted Disease Clinic: Philadelphia, 2019-2023. VL - 52 UR - https://stacks.cdc.gov/view/cdc/261237 ER -
Changes in Donor Human Milk Use Among US Hospitals: 2018-2024.

Awan, Sofia ;

O'Connor, Lauren

August 2025 | Pediatrics, 2025, v. 156, no. 2

Pasteurized donor human milk (PDHM) is recommended when mother's own milk is unavailable or contraindicated.1,2 Guidance prioritizes human milk for infants with very low birth weight (<1500 g) as it protects against complications, such as necrotizing enterocolitis.3 However, guidance on PDHM use among other newborns is lacking, particularly those in Level I neonatal care.4 Using 2018-2024 Maternity Practices in Infant Nutrition and Care (mPINC) data, we describe trends in DHM use among US hospitals by level of care and characteristics of hospitals that provided DHM

10/09/2026

Supporting Files

Title : Changes in Donor Human Milk Use Among US Hospitals: 2018-2024. Personal Author(s) : Awan, Sofia;O'Connor, Lauren;Kortsmit, Katherine;Anstey, Erica H.;Gosdin, Lucas; Published Date : August 2025 Pages in Document : e2024069469(8 pdf pages) Source : Pediatrics, 2025, v. 156, no. 2 DOI : https://doi.org/10.1542/peds.2024-069469 Journal Title : Pediatrics
Awan, S., O'Connor, L., Kortsmit, K., Anstey, E. H., & Gosdin, L. (2025). Changes in Donor Human Milk Use Among US Hospitals: 2018-2024. Pediatrics, 156(2). https://doi.org/10.1542/peds.2024-069469

Awan, Sofia, Lauren O'Connor, Katherine Kortsmit, Erica H. Anstey, and Lucas Gosdin. "Changes in Donor Human Milk Use Among US Hospitals: 2018-2024." Pediatrics 156, no. 2 (2025). https://doi.org/10.1542/peds.2024-069469.

Awan, Sofia, et al. "Changes in Donor Human Milk Use Among US Hospitals: 2018-2024." Pediatrics, vol. 156, no. 2, 2025. Stacks. https://doi.org/10.1542/peds.2024-069469.
Export RIS Citation Information. TY - Journal Article AU - Awan, Sofia AU - O'Connor, Lauren AU - Kortsmit, Katherine AU - Anstey, Erica H. AU - Gosdin, Lucas AB - Pasteurized donor human milk (PDHM) is recommended when mother's own milk is unavailable or contraindicated.1,2 Guidance prioritizes human milk for infants with very low birth weight (<1500 g) as it protects against complications, such as necrotizing enterocolitis.3 However, guidance on PDHM use among other newborns is lacking, particularly those in Level I neonatal care.4 Using 2018-2024 Maternity Practices in Infant Nutrition and Care (mPINC) data, we describe trends in DHM use among US hospitals by level of care and characteristics of hospitals that provided DHM AB - Author manuscript AN - cdc:261236 C4 - PMC12355910 DO - https://doi.org/10.1542/peds.2024-069469 IS - 2 J2 - Pediatrics KW - Pregnancy KW - Enterocolitis, Necrotizing KW - Mothers KW - Infant, Very Low Birth Weight KW - Milk, Human KW - Infant KW - Pregnancy KW - Infant KW - Enterocolitis, Necrotizing KW - Milk, Human KW - Mothers KW - Infant, Very Low Birth Weight LA - eng PY - 2025 T2 - Pediatrics T2 - Pediatrics, 2025, v. 156, no. 2 TI - Changes in Donor Human Milk Use Among US Hospitals: 2018-2024. VL - 156 UR - https://stacks.cdc.gov/view/cdc/261236 ER -
Assessing User Engagement With an Interactive Mapping Dashboard For Overdose Prevention Informed by Predictive Modeling in Rhode Island.

Skinner, Alexandra ;

Neill, Daniel B.

November 28, 2025 | Journal of Public Health Management and Practice : JPHMP, 2025, v. 31, no. 6

Predictive modeling can identify neighborhoods at elevated risk of future overdose death and may assist community organizations' decisions about harm reduction resource allocation. In Rhode Island, PROVIDENT is a research initiative and randomized community intervention trial that developed and validated a machine learning model that predicts futur ...

10/09/2026

Supporting Files

Title : Assessing User Engagement With an Interactive Mapping Dashboard For Overdose Prevention Informed by Predictive Modeling in Rhode Island. Personal Author(s) : Skinner, Alexandra;Neill, Daniel B.;Allen, Bennett;Krieger, Maxwell;Gray, Jesse Yedinak;Pratty, Claire;Macmadu, Alexandria;Goedel, William C.;Samuels, Elizabeth A.;Ahern, Jennifer;Cerdá, Magdalena;Marshall, Brandon D. L.; Published Date : November 28, 2025 Pages in Document : E330-E337 (15 pdf pages) Source : Journal of Public Health Management and Practice : JPHMP, 2025, v. 31, no. 6 DOI : https://doi.org/10.1097/PHH.0000000000002200 Journal Title : Journal of Public Health Management and Practice : JPHMP
Skinner, A., Neill, D. B., Allen, B., Krieger, M., Gray, J. Y., Pratty, C., Macmadu, A., Goedel, W. C., Samuels, E. A., Ahern, J., Cerdá, M., & Marshall, B. D. L. (2025). Assessing User Engagement With an Interactive Mapping Dashboard For Overdose Prevention Informed by Predictive Modeling in Rhode Island. Journal of Public Health Management and Practice : JPHMP, 31(6). https://doi.org/10.1097/PHH.0000000000002200

Skinner, Alexandra, Daniel B. Neill, Bennett Allen, Maxwell Krieger, Jesse Yedinak Gray, Claire Pratty, and Alexandria Macmadu, et al.. "Assessing User Engagement With an Interactive Mapping Dashboard For Overdose Prevention Informed by Predictive Modeling in Rhode Island." Journal of Public Health Management and Practice : JPHMP 31, no. 6 (2025). https://doi.org/10.1097/PHH.0000000000002200.

Skinner, Alexandra, et al. "Assessing User Engagement With an Interactive Mapping Dashboard For Overdose Prevention Informed by Predictive Modeling in Rhode Island." Journal of Public Health Management and Practice : JPHMP, vol. 31, no. 6, 2025. Stacks. https://doi.org/10.1097/PHH.0000000000002200.
Export RIS Citation Information. TY - Journal Article AU - Skinner, Alexandra AU - Neill, Daniel B. AU - Allen, Bennett AU - Krieger, Maxwell AU - Gray, Jesse Yedinak AU - Pratty, Claire AU - Macmadu, Alexandria AU - Goedel, William C. AU - Samuels, Elizabeth A. AU - Ahern, Jennifer AU - Cerdá, Magdalena AU - Marshall, Brandon D. L. AB - Predictive modeling can identify neighborhoods at elevated risk of future overdose death and may assist community organizations' decisions about harm reduction resource allocation. In Rhode Island, PROVIDENT is a research initiative and randomized community intervention trial that developed and validated a machine learning model that predicts future overdose at a census block group (CBG) level. The PROVIDENT model prioritizes the top 20th percentile of CBGs at highest risk of future overdose death over the subsequent 6-month period. In CBGs assigned to the trial intervention arm, these predictions are then displayed for partnering community organizations via an interactive mapping dashboard. AB - To evaluate whether CBGs prioritized by the PROVIDENT model were associated with increased user engagement via an online dashboard for fatal overdose forecasting and resource planning. AB - We estimated prevalence ratios using modified Poisson regression models, adjusted for CBG-level characteristics that may confound the relationship between model predictions and dashboard engagement. AB - We used CBG-level data in Rhode Island (N = 809) from November 2021 to July 2024. AB - Our exposure of interest was whether each CBG was prioritized by the PROVIDENT model and shown as prioritized on the interactive mapping dashboard. AB - Our primary outcome was whether a dashboard user from any partnering community organization engaged (eg, clicked, interacted with dashboard elements, or completed assessment or planning surveys) with each CBG on the interactive mapping dashboard. AB - After adjusting for previous model predictions and dashboard engagement, nonfatal overdose counts, and distribution of race and ethnicity, poverty, unemployment, and rent burden, dashboard users were 1.0 to 2.4 times as likely to engage with CBGs prioritized by the PROVIDENT model that were shown as prioritized on the dashboard as compared to CBGs that were prioritized by the PROVIDENT model that were blinded on the dashboard. AB - Interactive mapping tools with predictive modeling may be useful to support community-based harm reduction organizations in the allocation of resources to neighborhoods predicted to be at high risk of future overdose death. AB - Author manuscript AN - cdc:261235 C4 - PMC12661414 DO - https://doi.org/10.1097/PHH.0000000000002200 IS - 6 J2 - Journal of Public Health Management and Practice : JPHMP KW - Female KW - Forecasting KW - Male KW - Humans KW - Middle Aged KW - Adult KW - Drug Overdose KW - dashboard implementation KW - overdose prevention KW - predictive modeling KW - Humans KW - Drug Overdose KW - Female KW - Male KW - Adult KW - Forecasting KW - Middle Aged LA - eng PY - 2025 T2 - Journal of Public Health Management and Practice : JPHMP T2 - Journal of Public Health Management and Practice : JPHMP, 2025, v. 31, no. 6 TI - Assessing User Engagement With an Interactive Mapping Dashboard For Overdose Prevention Informed by Predictive Modeling in Rhode Island. VL - 31 UR - https://stacks.cdc.gov/view/cdc/261235 ER -
Prevalence of Congenital Heart Defects Among Children With and Without Diagnosed Fetal Alcohol Spectrum Disorders, 2016-2022.

Dorsey, Amanda N. ;

Downing, Karrie F.

September 2025 | Drug and Alcohol Dependence, 2025, v. 274

Alcohol use during pregnancy might be a risk factor for some congenital heart defects (CHDs), but CHD prevalence among children with fetal alcohol spectrum disorders (FASDs) is not well understood. We used two administrative databases to explore CHD prevalence among U.S. children with and without FASDs.We limited 2016-2022 Merative™ MarketScan® Mul ...

10/09/2026

Supporting Files

Title : Prevalence of Congenital Heart Defects Among Children With and Without Diagnosed Fetal Alcohol Spectrum Disorders, 2016-2022. Personal Author(s) : Dorsey, Amanda N.;Downing, Karrie F.;Deputy, Nicholas P.;Weber, Mary Kate;Howards, Penelope P.; Published Date : September 2025 Pages in Document : 112790 (17 pdf pages) Source : Drug and Alcohol Dependence, 2025, v. 274 DOI : https://doi.org/10.1016/j.drugalcdep.2025.112790 Journal Title : Drug and Alcohol Dependence
Dorsey, A. N., Downing, K. F., Deputy, N. P., Weber, M. K., & Howards, P. P. (2025). Prevalence of Congenital Heart Defects Among Children With and Without Diagnosed Fetal Alcohol Spectrum Disorders, 2016-2022. Drug and Alcohol Dependence, 274. https://doi.org/10.1016/j.drugalcdep.2025.112790

Dorsey, Amanda N., Karrie F. Downing, Nicholas P. Deputy, Mary Kate Weber, and Penelope P. Howards. "Prevalence of Congenital Heart Defects Among Children With and Without Diagnosed Fetal Alcohol Spectrum Disorders, 2016-2022." Drug and Alcohol Dependence 274 (2025). https://doi.org/10.1016/j.drugalcdep.2025.112790.

Dorsey, Amanda N., et al. "Prevalence of Congenital Heart Defects Among Children With and Without Diagnosed Fetal Alcohol Spectrum Disorders, 2016-2022." Drug and Alcohol Dependence, vol. 274, 2025. Stacks. https://doi.org/10.1016/j.drugalcdep.2025.112790.
Export RIS Citation Information. TY - Journal Article AU - Dorsey, Amanda N. AU - Downing, Karrie F. AU - Deputy, Nicholas P. AU - Weber, Mary Kate AU - Howards, Penelope P. AB - Alcohol use during pregnancy might be a risk factor for some congenital heart defects (CHDs), but CHD prevalence among children with fetal alcohol spectrum disorders (FASDs) is not well understood. We used two administrative databases to explore CHD prevalence among U.S. children with and without FASDs. AB - We limited 2016-2022 Merative™ MarketScan® Multi-State Medicaid and Commercial data to children ≤ 17 years old with ≥ 1 year of continuous enrollment with complete data on mental health and substance use services. CHD prevalence was calculated by FASD status, overall and by age group, using log-binomial prevalence ratios (PRs) and 95 % confidence intervals (CIs). Analyses were repeated after matching on enrollment length, and age and year at the start of enrollment. In the Medicaid sample, we also stratified by demographic characteristics and analyzed severe and non-severe CHD diagnoses separately. Multidimensional bias analysis considered the influence of unmeasured prenatal tobacco exposure. AB - Among 8732,345 children in the Medicaid sample, 5.2 % with FASDs and 1.0 % without FASDs had CHDs (matched cohort PR = 3.4 [CI: 2.8, 4.1]). PRs were similar when stratified by sex and race and ethnicity, and when looking at exclusively severe or non-severe CHDs. Among 10,567,765 children in the commercial claims sample, 3.0 % with FASDs and 0.6 % without FASDs had CHDs (matched cohort PR= 4.6 [CI: 3.3, 6.4]). AB - CHDs were more common among children with FASDs compared to those without FASDs in two administrative database samples. Increased provider awareness about CHDs as a potential FASD comorbidity may improve timely CHD care. AB - Author manuscript AN - cdc:261234 C4 - PMC12330177 DO - https://doi.org/10.1016/j.drugalcdep.2025.112790 J2 - Drug and Alcohol Dependence KW - Pregnancy KW - Adolescent KW - Female KW - Fetal Alcohol Spectrum Disorders KW - Prenatal Exposure Delayed Effects KW - Medicaid KW - Child KW - Databases, Factual KW - Risk Factors KW - Infant KW - Prevalence KW - Heart Defects, Congenital KW - Male KW - Humans KW - Child, Preschool KW - Fetal Alcohol Spectrum Disorders KW - Congenital Heart Defects KW - Substance-Related Disorders KW - Medicaid KW - Comorbidity KW - Humans KW - Fetal Alcohol Spectrum Disorders KW - Female KW - Heart Defects, Congenital KW - Child KW - Prevalence KW - Male KW - Pregnancy KW - Adolescent KW - Child, Preschool KW - Infant KW - Medicaid KW - Prenatal Exposure Delayed Effects KW - Databases, Factual KW - Risk Factors LA - eng PY - 2025 T2 - Drug and Alcohol Dependence T2 - Drug and Alcohol Dependence, 2025, v. 274 TI - Prevalence of Congenital Heart Defects Among Children With and Without Diagnosed Fetal Alcohol Spectrum Disorders, 2016-2022. VL - 274 UR - https://stacks.cdc.gov/view/cdc/261234 ER -
Cost of Colorectal Cancer Screening in Two Tribal Health Organizations in Alaska.

Tangka, Florence K. L. ;

Hoover, Sonja

November 2025 | Cancer Causes & Control : CCC, 2025, v. 36, no. 11

We conducted a comprehensive assessment of the resources required to undergo colorectal cancer (CRC) screening in two Alaska Native tribal health organizations.We evaluated the cost of CRC screening at Maniilaq Association and Bristol Bay Area Health Corporation, and the communities they serve. We developed a tailored data collection tool to gather ...

10/09/2026

Supporting Files

Title : Cost of Colorectal Cancer Screening in Two Tribal Health Organizations in Alaska. Personal Author(s) : Tangka, Florence K. L.;Hoover, Sonja;Krudy, Mark;Brown, Cara;Tessier, Susan;Hodson, Willyam;Redwood, Diana;Smayda, Lauren;Haverkamp, Donald;Poole, Michelle;Subramanian, Sujha; Published Date : November 2025 Pages in Document : 1377-1383 (10 pdf pages) Source : Cancer Causes & Control : CCC, 2025, v. 36, no. 11 DOI : https://doi.org/10.1007/s10552-025-02036-w Journal Title : Cancer Causes & Control : CCC
Tangka, F. K. L., Hoover, S., Krudy, M., Brown, C., Tessier, S., Hodson, W., Redwood, D., Smayda, L., Haverkamp, D., Poole, M., & Subramanian, S. (2025). Cost of Colorectal Cancer Screening in Two Tribal Health Organizations in Alaska. Cancer Causes & Control : CCC, 36(11). https://doi.org/10.1007/s10552-025-02036-w

Tangka, Florence K. L., Sonja Hoover, Mark Krudy, Cara Brown, Susan Tessier, Willyam Hodson, and Diana Redwood, et al.. "Cost of Colorectal Cancer Screening in Two Tribal Health Organizations in Alaska." Cancer Causes & Control : CCC 36, no. 11 (2025). https://doi.org/10.1007/s10552-025-02036-w.

Tangka, Florence K. L., et al. "Cost of Colorectal Cancer Screening in Two Tribal Health Organizations in Alaska." Cancer Causes & Control : CCC, vol. 36, no. 11, 2025. Stacks. https://doi.org/10.1007/s10552-025-02036-w.
Export RIS Citation Information. TY - Journal Article AU - Tangka, Florence K. L. AU - Hoover, Sonja AU - Krudy, Mark AU - Brown, Cara AU - Tessier, Susan AU - Hodson, Willyam AU - Redwood, Diana AU - Smayda, Lauren AU - Haverkamp, Donald AU - Poole, Michelle AU - Subramanian, Sujha AB - We conducted a comprehensive assessment of the resources required to undergo colorectal cancer (CRC) screening in two Alaska Native tribal health organizations. AB - We evaluated the cost of CRC screening at Maniilaq Association and Bristol Bay Area Health Corporation, and the communities they serve. We developed a tailored data collection tool to gather data from health clinics. We calculated the cost of screening tests and patient costs. We also conducted interviews with clinic representatives to identify contextual factors that can affect cost estimates. AB - The cost of fecal immunochemical tests and fecal occult blood tests ranged from $53 to $76. The cost of the colonoscopy procedure ranged from $2,600 to $4,066. Travel costs, including per diem, ranged from $1,561 to $1,740. The cost of missed work was estimated to be $1,008 for patients and medical escorts for both communities. The total cost of receiving a colonoscopy, including procedural costs, travel costs, and the cost of missed work, ranged from $5,348 to $6,635. AB - We found the cost of the screening tests, travel costs and the cost of missed work to undergo CRC screening were higher in Alaska than national averages. Program planning could benefit from accounting for the costs and additional resources needed in Alaska due to the geography of the state and the location of providers and facilities. AB - Author manuscript AN - cdc:261233 C4 - PMC12362863 DO - https://doi.org/10.1007/s10552-025-02036-w IS - 11 J2 - Cancer Causes & Control : CCC KW - Occult Blood KW - Health Services, Indigenous KW - Female KW - Colonoscopy KW - Colorectal Neoplasms KW - Mass Screening KW - Aged KW - Early Detection of Cancer KW - Alaska Natives KW - Male KW - Middle Aged KW - Humans KW - Health Care Costs KW - Colorectal cancer KW - cancer screening KW - patient navigation KW - program cost KW - Alaska public health KW - Aged KW - Female KW - Humans KW - Male KW - Middle Aged KW - Alaska Natives KW - Colonoscopy KW - Colorectal Neoplasms KW - Early Detection of Cancer KW - Health Care Costs KW - Mass Screening KW - Occult Blood KW - Health Services, Indigenous LA - eng PY - 2025 T2 - Cancer Causes & Control : CCC T2 - Cancer Causes & Control : CCC, 2025, v. 36, no. 11 TI - Cost of Colorectal Cancer Screening in Two Tribal Health Organizations in Alaska. VL - 36 UR - https://stacks.cdc.gov/view/cdc/261233 ER -
Characterisation of a Persistent SARS-CoV-2 Infection Lasting More Than 750 Days in a Person Living With HIV: a Genomic Analysis.

Velasquez-Reyes, Joseline M ;

Schaeffer, Beau

September 2025 | The Lancet. Microbe, 2025, v. 6, no. 9

People who are immunocompromised can develop persistent SARS-CoV-2 infections. Several viral mutations accumulated during the course of such persistent infections have also been observed in prominent variants of concern (VOCs). Here, we characterise persistent infection and viral evolution of SARS-CoV-2 lasting more than 750 days in a person with a ...

10/09/2026

Supporting Files

Title : Characterisation of a Persistent SARS-CoV-2 Infection Lasting More Than 750 Days in a Person Living With HIV: a Genomic Analysis. Personal Author(s) : Velasquez-Reyes, Joseline M;Schaeffer, Beau;Curry, Scott R;Overbeck, Victoria;Sher-Jan, Cole;Taylor, Bradford P;Turcinovic, Jacquelyn;Kuppalli, Krutika;Connor, John H;Hanage, William P; Published Date : September 2025 Pages in Document : 101122 (20 pdf pages) Source : The Lancet. Microbe, 2025, v. 6, no. 9 DOI : https://doi.org/10.1016/j.lanmic.2025.101122 Journal Title : The Lancet. Microbe
Velasquez-Reyes, J. M., Schaeffer, B., Curry, S. R., Overbeck, V., Sher-Jan, C., Taylor, B. P., Turcinovic, J., Kuppalli, K., Connor, J. H., & Hanage, W. P. (2025). Characterisation of a Persistent SARS-CoV-2 Infection Lasting More Than 750 Days in a Person Living With HIV: a Genomic Analysis. The Lancet. Microbe, 6(9). https://doi.org/10.1016/j.lanmic.2025.101122

Velasquez-Reyes, Joseline M, Beau Schaeffer, Scott R Curry, Victoria Overbeck, Cole Sher-Jan, Bradford P Taylor, Jacquelyn Turcinovic, Krutika Kuppalli, John H Connor, and William P Hanage. "Characterisation of a Persistent SARS-CoV-2 Infection Lasting More Than 750 Days in a Person Living With HIV: a Genomic Analysis." The Lancet. Microbe 6, no. 9 (2025). https://doi.org/10.1016/j.lanmic.2025.101122.

Velasquez-Reyes, Joseline M, et al. "Characterisation of a Persistent SARS-CoV-2 Infection Lasting More Than 750 Days in a Person Living With HIV: a Genomic Analysis." The Lancet. Microbe, vol. 6, no. 9, 2025. Stacks. https://doi.org/10.1016/j.lanmic.2025.101122.
Export RIS Citation Information. TY - Journal Article AU - Velasquez-Reyes, Joseline M AU - Schaeffer, Beau AU - Curry, Scott R AU - Overbeck, Victoria AU - Sher-Jan, Cole AU - Taylor, Bradford P AU - Turcinovic, Jacquelyn AU - Kuppalli, Krutika AU - Connor, John H AU - Hanage, William P AB - People who are immunocompromised can develop persistent SARS-CoV-2 infections. Several viral mutations accumulated during the course of such persistent infections have also been observed in prominent variants of concern (VOCs). Here, we characterise persistent infection and viral evolution of SARS-CoV-2 lasting more than 750 days in a person with advanced HIV-1 infection. AB - Between March, 2021, and July, 2022, eight clinical specimens were collected from a person living with HIV, neither receiving antiretroviral therapy nor virally suppressed, and presumed to have been initially infected with SARS-CoV-2 in mid-May, 2020. Viral RNA was extracted from each swab and an amplicon-based sequencing approach was used for genomic analysis of SARS-CoV-2. Variable sites were characterised at the consensus and subconsensus levels, and phylogenetic tools were applied to analyse viral evolution. Publicly available SARS-CoV-2 sequences from GenBank were leveraged to contextualise our sequenced samples and identify any potential evidence of transmission. AB - Genomes formed a monophyletic cluster in the B.1 lineage. 68 consensus and 67 subconsensus single nucleotide variants were observed over the course of infection. The intrahost clock rate remained similar to that of the interhost rate in contemporaneous community sequences (6·74 × 10 AB - [95% credible interval 5·05 × 10 AB - to 8·54 × 10 AB - ] substitutions per site per year vs 6·11 × 10 AB - [5·54 × 10 AB - to 6·66 × 10 AB - ]). Mutations grouped into two distinct subpopulations present throughout infection. 10 non-synonymous mutations in the spike protein gene were at positions in common with those defining the omicron lineage (BA.1 or BA.2), of which nine were present before November, 2021. Nine of 18 substitutions present throughout infection were rare in online databases, suggesting a lack of long transmission chains descending from this individual. AB - Convergent SARS-CoV-2 evolution, both in and outside the spike protein, observed in this study suggests parallels with the evolutionary process leading to emergence of the omicron VOC. The inferred absence of onward infections might indicate a loss of transmissibility during adaptation to a single host. Our results underscore the importance of appropriate treatment to cure persistent SARS-CoV-2 infections and monitoring them to understand how mutations contribute to viral adaptation. AB - National Institute of General Medical Sciences of the National Institutes of Health, Centers for Disease Control and Prevention, the National Institute of Allergy and Infectious Diseases, MassCPR, and Morris Singer Foundation. AB - Author manuscript AN - cdc:261232 C4 - PMC12633830 DO - https://doi.org/10.1016/j.lanmic.2025.101122 IS - 9 J2 - The Lancet. Microbe KW - Female KW - RNA, Viral KW - SARS-CoV-2 KW - Evolution, Molecular KW - Phylogeny KW - COVID-19 KW - Genome, Viral KW - Persistent Infection KW - Male KW - Genomics KW - Middle Aged KW - Humans KW - HIV Infections KW - Mutation KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - HIV Infections KW - Genome, Viral KW - Phylogeny KW - Mutation KW - Male KW - Persistent Infection KW - Genomics KW - RNA, Viral KW - Evolution, Molecular KW - Middle Aged KW - Female LA - eng PY - 2025 T2 - The Lancet. Microbe T2 - The Lancet. Microbe, 2025, v. 6, no. 9 TI - Characterisation of a Persistent SARS-CoV-2 Infection Lasting More Than 750 Days in a Person Living With HIV: a Genomic Analysis. VL - 6 UR - https://stacks.cdc.gov/view/cdc/261232 ER -
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus.

Ma, Kevin C. ;

Surie, Diya

March 2026 | Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 2026, v. 82, no. 3

Adults hospitalized with acute respiratory infections, including respiratory syncytial virus (RSV), often have multiple underlying conditions. Few data are available on the combined effect of conditions on risk of severe outcomes from RSV disease.We enrolled adults hospitalized with RSV at 26 hospitals in 20 US states admitted January 2022-July 202 ...

10/09/2026

Supporting Files

Title : Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus. Personal Author(s) : Ma, Kevin C.;Surie, Diya;Zhu, Yuwei;Grijalva, Carlos G.;Blair, Paul W.;Safdar, Basmah;Ginde, Adit A.;Peltan, Ithan D.;Brown, Samuel M.;Gaglani, Manjusha;Ghamande, Shekhar;Columbus, Cristie;Mohr, Nicholas M.;Gibbs, Kevin W.;Hager, David N.;Prekker, Matthew E.;Gong, Michelle N.;Mohamed, Amira;Johnson, Nicholas J.;Steingrub, Jay S.;Khan, Akram;Hough, Catherine L.;Duggal, Abhijit;Gordon, Alexandra June;Qadir, Nida;Chang, Steven Y.;Mallow, Christopher;Busse, Laurence W.;Kwon, Jennie H.;Exline, Matthew C.;Vaughn, Ivana A.;Ramesh, Mayur;Lauring, Adam S.;Martin, Emily T.;Leis, Aleda M.;Mosier, Jarrod M.;Harris, Estelle S.;Baughman, Adrienne;Johnson, Cassandra;Casey, Jonathan D.;Halasa, Natasha;Chappell, James D.;Lewis, Nathaniel;Ellington, Sascha;Self, Wesley H.;Dawood, Fatimah S.; Published Date : March 2026 Pages in Document : e561-e570 (22 pdf pages) Source : Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 2026, v. 82, no. 3 DOI : https://doi.org/10.1093/cid/ciaf405 Journal Title : Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America
Ma, K. C., Surie, D., Zhu, Y., Grijalva, C. G., Blair, P. W., Safdar, B., Ginde, A. A., Peltan, I. D., Brown, S. M., Gaglani, M., Ghamande, S., Columbus, C., Mohr, N. M., Gibbs, K. W., Hager, D. N., Prekker, M. E., Gong, M. N., Mohamed, A., Johnson, N. J., ... Dawood, F. S. (2026). Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 82(3). https://doi.org/10.1093/cid/ciaf405

Ma, Kevin C., Diya Surie, Yuwei Zhu, Carlos G. Grijalva, Paul W. Blair, Basmah Safdar, and Adit A. Ginde, et al.. "Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 82, no. 3 (2026). https://doi.org/10.1093/cid/ciaf405.

Ma, Kevin C., et al. "Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 82, no. 3, 2026. Stacks. https://doi.org/10.1093/cid/ciaf405.
Export RIS Citation Information. TY - Journal Article AU - Ma, Kevin C. AU - Surie, Diya AU - Zhu, Yuwei AU - Grijalva, Carlos G. AU - Blair, Paul W. AU - Safdar, Basmah AU - Ginde, Adit A. AU - Peltan, Ithan D. AU - Brown, Samuel M. AU - Gaglani, Manjusha AU - Ghamande, Shekhar AU - Columbus, Cristie AU - Mohr, Nicholas M. AU - Gibbs, Kevin W. AU - Hager, David N. AU - Prekker, Matthew E. AU - Gong, Michelle N. AU - Mohamed, Amira AU - Johnson, Nicholas J. AU - Steingrub, Jay S. AU - Khan, Akram AU - Hough, Catherine L. AU - Duggal, Abhijit AU - Gordon, Alexandra June AU - Qadir, Nida AU - Chang, Steven Y. AU - Mallow, Christopher AU - Busse, Laurence W. AU - Kwon, Jennie H. AU - Exline, Matthew C. AU - Vaughn, Ivana A. AU - Ramesh, Mayur AU - Lauring, Adam S. AU - Martin, Emily T. AU - Leis, Aleda M. AU - Mosier, Jarrod M. AU - Harris, Estelle S. AU - Baughman, Adrienne AU - Johnson, Cassandra AU - Casey, Jonathan D. AU - Halasa, Natasha AU - Chappell, James D. AU - Lewis, Nathaniel AU - Ellington, Sascha AU - Self, Wesley H. AU - Dawood, Fatimah S. AB - Adults hospitalized with acute respiratory infections, including respiratory syncytial virus (RSV), often have multiple underlying conditions. Few data are available on the combined effect of conditions on risk of severe outcomes from RSV disease. AB - We enrolled adults hospitalized with RSV at 26 hospitals in 20 US states admitted January 2022-July 2024. Seventeen underlying conditions were selected after excluding those with rare prevalence (≤1%) or high pairwise correlation (≥0.7). We applied Bayesian profile regression to identify profiles of conditions associated with increased risk of RSV severe outcomes, stratifying among adults aged 18-59 and ≥60 years. AB - We analyzed data from 1111 adults hospitalized with RSV (median [IQR] age, 66 [53-75] years). Among 397 adults aged 18-59 years, 2 profiles were identified: (1) minimal prevalence with fewer underlying conditions and a posterior median intensive care unit (ICU) admission risk of 21% (95% credible interval, 16%-25%) and (2) cardiorenal/diabetes with frequent heart failure, chronic kidney disease, diabetes, and increased ICU admission risk (37% [27%-48%]). Among 714 adults aged 60 years and older, 4 profiles were identified: (1) minimal prevalence (ICU admission risk, 22% [18%-26%]), (2) cardiorenal/diabetes (27% [21%-34%]), (3) hematologic malignancy and transplant receipt (12% [6%-21%]), and (4) chronic pulmonary disease with home oxygen dependence (44% [25%-66%]). AB - Distinct underlying condition profiles with varying risks of critical illness were observed among inpatients with RSV. These findings could support recognition of high-risk patients to inform RSV prevention strategies and suggest that the role of multimorbidity in severe RSV disease risk warrants further attention. AB - Author manuscript AN - cdc:261230 C4 - PMC13193655 DO - https://doi.org/10.1093/cid/ciaf405 IS - 3 J2 - Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America KW - Adolescent KW - Female KW - Multimorbidity KW - Bayes Theorem KW - Respiratory Syncytial Virus Infections KW - Aged KW - Young Adult KW - Risk Factors KW - Prevalence KW - Hospitalization KW - Male KW - Humans KW - Middle Aged KW - Adult KW - Respiratory Syncytial Virus, Human KW - respiratory syncytial virus KW - risk factors KW - underlying conditions KW - statistical clustering KW - ICU admission KW - Humans KW - Respiratory Syncytial Virus Infections KW - Middle Aged KW - Male KW - Female KW - Aged KW - Adult KW - Multimorbidity KW - Hospitalization KW - Adolescent KW - Young Adult KW - Risk Factors KW - Prevalence KW - Respiratory Syncytial Virus, Human KW - Bayes Theorem LA - eng PY - 2026 T2 - Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America T2 - Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 2026, v. 82, no. 3 TI - Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus. VL - 82 UR - https://stacks.cdc.gov/view/cdc/261230 ER -
Methicillin-Resistant Staphylococcus Aureus Bacteremia Relapses Show Diverse Genomic Profiles But Convergence in Bacteremia-Associated Genes.

Talbot, Brooke M. ;

Jacko, Natasia F.

December 2025 | The Journal of Infectious Diseases, 2025, v. 232, no. 6

Recurrence of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a high risk complication for patients. Distinguishing persistent lineages from new infections is not standardized across clinical studies.We investigated factors contributing to recurrence of MRSA bacteremia among subjects in Philadelphia, Pennsylvania. Subject demograph ...

10/09/2026

Supporting Files

Title : Methicillin-Resistant Staphylococcus Aureus Bacteremia Relapses Show Diverse Genomic Profiles But Convergence in Bacteremia-Associated Genes. Personal Author(s) : Talbot, Brooke M.;Jacko, Natasia F.;Hofstetter, Katrina;Alahakoon, Tara;Bouiller, Kevin;Read, Timothy D.;David, Michael Z.; Published Date : December 2025 Pages in Document : 1338-1350 (21 pdf pages) Source : The Journal of Infectious Diseases, 2025, v. 232, no. 6 DOI : https://doi.org/10.1093/infdis/jiaf352 Journal Title : The Journal of Infectious Diseases
Talbot, B. M., Jacko, N. F., Hofstetter, K., Alahakoon, T., Bouiller, K., Read, T. D., & David, M. Z. (2025). Methicillin-Resistant Staphylococcus Aureus Bacteremia Relapses Show Diverse Genomic Profiles But Convergence in Bacteremia-Associated Genes. The Journal of Infectious Diseases, 232(6). https://doi.org/10.1093/infdis/jiaf352

Talbot, Brooke M., Natasia F. Jacko, Katrina Hofstetter, Tara Alahakoon, Kevin Bouiller, Timothy D. Read, and Michael Z. David. "Methicillin-Resistant Staphylococcus Aureus Bacteremia Relapses Show Diverse Genomic Profiles But Convergence in Bacteremia-Associated Genes." The Journal of Infectious Diseases 232, no. 6 (2025). https://doi.org/10.1093/infdis/jiaf352.

Talbot, Brooke M., et al. "Methicillin-Resistant Staphylococcus Aureus Bacteremia Relapses Show Diverse Genomic Profiles But Convergence in Bacteremia-Associated Genes." The Journal of Infectious Diseases, vol. 232, no. 6, 2025. Stacks. https://doi.org/10.1093/infdis/jiaf352.
Export RIS Citation Information. TY - Journal Article AU - Talbot, Brooke M. AU - Jacko, Natasia F. AU - Hofstetter, Katrina AU - Alahakoon, Tara AU - Bouiller, Kevin AU - Read, Timothy D. AU - David, Michael Z. AB - Recurrence of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a high risk complication for patients. Distinguishing persistent lineages from new infections is not standardized across clinical studies. AB - We investigated factors contributing to recurrence of MRSA bacteremia among subjects in Philadelphia, Pennsylvania. Subject demographics and clinical history were collected and paired with whole-genome sequences of infection isolates. Recurrent bacteremia episodes were recorded and defined as relapse infections (same lineage) or new infections by genomic criteria, where a relapse contained isolates ≤ 25 single nucleotide polymorphisms (SNP) different, and by clinical criteria. All isolates were assessed for pairwise SNP distances, common mutations, and signatures of within-host adaptation using the McDonald-Kreitman test. Clusters of transmission between relapse-associated isolates and other subject lineages were identified. AB - Among 411 sequential subjects with MRSA bacteremia, 32 experienced recurrent bacteremia episodes, with 24 subjects having exclusively relapse infections, 6 with infections exclusively from a new strain, and 2 patients with both relapse and new infections. No concordance between a genomic and a clinical definition of relapse was evident (Cohen κ = 0.18; confidence interval, -0.41). Recurrence-associated lineages exhibited signatures of positive selection (G test, < 0.01). Genes with SNPs occurring in multiple relapse lineages have roles in antibiotic resistance and virulence, including 5 lineages with mutations in mprF and 3 lineages with mutations in rpoB, which corresponded with evolved phenotypic changes in daptomycin and rifampin resistance. AB - Recurrent infections have a diverse strain background. Relapses can be readily distinguished from newly acquired infections using genomic sequencing but not clinical criteria. AB - Author manuscript AN - cdc:261229 C4 - PMC12718022 DO - https://doi.org/10.1093/infdis/jiaf352 IS - 6 J2 - The Journal of Infectious Diseases KW - Bacteremia KW - Female KW - Recurrence KW - Methicillin-Resistant Staphylococcus aureus KW - Aged KW - Aged, 80 and over KW - Male KW - Polymorphism, Single Nucleotide KW - Middle Aged KW - Humans KW - Anti-Bacterial Agents KW - Whole Genome Sequencing KW - Adult KW - Genome, Bacterial KW - Staphylococcal Infections KW - hospital epidemiology KW - genomic epidemiology KW - infection prevention KW - Humans KW - Bacteremia KW - Staphylococcal Infections KW - Methicillin-Resistant Staphylococcus aureus KW - Male KW - Female KW - Recurrence KW - Middle Aged KW - Polymorphism, Single Nucleotide KW - Aged KW - Adult KW - Genome, Bacterial KW - Aged, 80 and over KW - Whole Genome Sequencing KW - Anti-Bacterial Agents LA - eng PY - 2025 T2 - The Journal of Infectious Diseases T2 - The Journal of Infectious Diseases, 2025, v. 232, no. 6 TI - Methicillin-Resistant Staphylococcus Aureus Bacteremia Relapses Show Diverse Genomic Profiles But Convergence in Bacteremia-Associated Genes. VL - 232 UR - https://stacks.cdc.gov/view/cdc/261229 ER -
Human Infections With Highly Pathogenic Avian Influenza A(H5N1) Viruses in the United States From March 2024 to May 2025.

Rolfes, Melissa A. ;

Kniss, Krista

November 2025 | Nature Medicine, 2025, v. 31, no. 11

Between March 2024 and October 2024, 46 human cases of highly pathogenic avian influenza (HPAI) A(H5N1) had been detected in the United States. The persistent panzootic spread of HPAI A(H5N1) viruses and continued detection of human cases presents an ongoing threat to public health. In this study, between November 2024 and May 2025, an additional 2 ...

10/09/2026

Supporting Files

Title : Human Infections With Highly Pathogenic Avian Influenza A(H5N1) Viruses in the United States From March 2024 to May 2025. Personal Author(s) : Rolfes, Melissa A.;Kniss, Krista;Kirby, Marie K.;Garg, Shikha;Reinhart, Katie;Davis, C. Todd;Murray, Erin L.;Wadford, Debra A.;Harriman, Kathleen;Zhu, Sophie;Liu, Caterina Y.;Morales, Christina;Lopez, Denise;Esbenshade, Laura;Trivedi, Kavita K.;Tobolowsky, Farrell A.;Dang, Thi;Unutzer, Anna;Krager, Steven;Baum, Kaylyn;Curren, Emily J.;Harrist, Alexia;Hand, Julie;Sokol, Theresa;Salinas, Andrea;Bunch, Amy;Haydel, Danielle;Fisher, Nicholas;Margrey, Sara F.;Billing, Laurie;Turabelidze, George;Goswitz, Jessica;Kavlak, Leslie;Gonzales, Emilio;Tillman, Whitney;Rollo, Susan;Hamid, Cherissa Abdul;Aragon, Deborah;Owen, Mackenzie;Kohnen, Allison;Hoehne, Amy;Weigel, Andy;Hennenfent, Andrew;Sepcic, Victoria;Southern, Tim;Beard, Cindy;Scholz, Ryan;Present, Sarah;Sutton, Melissa;Morse, Jennifer;Weinberg, Meghan;Eckel, Seth;Haupt, Thomas;Maxted, Angela;Potts-Shufelt, Karla;Daskalakis, Demetre C.;Durand, Lizette O.;Liu, Feng;Rambo-Martin, Benjamin;Lacek, Kristine A.;Frederick, Julia C.;Liddell, Jimma;Burnett, Natasha;Keong, Lisa M.;DaSilva, Juliana;Sheffield, Sydney R.;Wilson, Malania M.;Di, Han;Schatzman, Sabrina S.;Jang, Yunho;Iuliano, A. Danielle;Couture, Alexia;Budd, Alicia P.;Levine, Min Z.;Gubareva, Larisa V.;Shimabukuro, Tom T.;Uyeki, Timothy M.;Dugan, Vivien G.;Reed, Carrie;Olsen, Sonja J.; Published Date : November 2025 Pages in Document : 3889-3898 (34 pdf pages) Source : Nature Medicine, 2025, v. 31, no. 11 DOI : https://doi.org/10.1038/s41591-025-03905-2 Journal Title : Nature Medicine
Rolfes, M. A., Kniss, K., Kirby, M. K., Garg, S., Reinhart, K., Davis, C. T., Murray, E. L., Wadford, D. A., Harriman, K., Zhu, S., Liu, C. Y., Morales, C., Lopez, D., Esbenshade, L., Trivedi, K. K., Tobolowsky, F. A., Dang, T., Unutzer, A., Krager, S., ... Olsen, S. J. (2025). Human Infections With Highly Pathogenic Avian Influenza A(H5N1) Viruses in the United States From March 2024 to May 2025. Nature Medicine, 31(11). https://doi.org/10.1038/s41591-025-03905-2

Rolfes, Melissa A., Krista Kniss, Marie K. Kirby, Shikha Garg, Katie Reinhart, C. Todd Davis, and Erin L. Murray, et al.. "Human Infections With Highly Pathogenic Avian Influenza A(H5N1) Viruses in the United States From March 2024 to May 2025." Nature Medicine 31, no. 11 (2025). https://doi.org/10.1038/s41591-025-03905-2.

Rolfes, Melissa A., et al. "Human Infections With Highly Pathogenic Avian Influenza A(H5N1) Viruses in the United States From March 2024 to May 2025." Nature Medicine, vol. 31, no. 11, 2025. Stacks. https://doi.org/10.1038/s41591-025-03905-2.
Export RIS Citation Information. TY - Journal Article AU - Rolfes, Melissa A. AU - Kniss, Krista AU - Kirby, Marie K. AU - Garg, Shikha AU - Reinhart, Katie AU - Davis, C. Todd AU - Murray, Erin L. AU - Wadford, Debra A. AU - Harriman, Kathleen AU - Zhu, Sophie AU - Liu, Caterina Y. AU - Morales, Christina AU - Lopez, Denise AU - Esbenshade, Laura AU - Trivedi, Kavita K. AU - Tobolowsky, Farrell A. AU - Dang, Thi AU - Unutzer, Anna AU - Krager, Steven AU - Baum, Kaylyn AU - Curren, Emily J. AU - Harrist, Alexia AU - Hand, Julie AU - Sokol, Theresa AU - Salinas, Andrea AU - Bunch, Amy AU - Haydel, Danielle AU - Fisher, Nicholas AU - Margrey, Sara F. AU - Billing, Laurie AU - Turabelidze, George AU - Goswitz, Jessica AU - Kavlak, Leslie AU - Gonzales, Emilio AU - Tillman, Whitney AU - Rollo, Susan AU - Hamid, Cherissa Abdul AU - Aragon, Deborah AU - Owen, Mackenzie AU - Kohnen, Allison AU - Hoehne, Amy AU - Weigel, Andy AU - Hennenfent, Andrew AU - Sepcic, Victoria AU - Southern, Tim AU - Beard, Cindy AU - Scholz, Ryan AU - Present, Sarah AU - Sutton, Melissa AU - Morse, Jennifer AU - Weinberg, Meghan AU - Eckel, Seth AU - Haupt, Thomas AU - Maxted, Angela AU - Potts-Shufelt, Karla AU - Daskalakis, Demetre C. AU - Durand, Lizette O. AU - Liu, Feng AU - Rambo-Martin, Benjamin AU - Lacek, Kristine A. AU - Frederick, Julia C. AU - Liddell, Jimma AU - Burnett, Natasha AU - Keong, Lisa M. AU - DaSilva, Juliana AU - Sheffield, Sydney R. AU - Wilson, Malania M. AU - Di, Han AU - Schatzman, Sabrina S. AU - Jang, Yunho AU - Iuliano, A. Danielle AU - Couture, Alexia AU - Budd, Alicia P. AU - Levine, Min Z. AU - Gubareva, Larisa V. AU - Shimabukuro, Tom T. AU - Uyeki, Timothy M. AU - Dugan, Vivien G. AU - Reed, Carrie AU - Olsen, Sonja J. AB - Between March 2024 and October 2024, 46 human cases of highly pathogenic avian influenza (HPAI) A(H5N1) had been detected in the United States. The persistent panzootic spread of HPAI A(H5N1) viruses and continued detection of human cases presents an ongoing threat to public health. In this study, between November 2024 and May 2025, an additional 24 cases have been reported for a total of 70 human cases of HPAI A(H5N1): 41 were exposed to dairy cows, 24 to commercial poultry, two to backyard poultry and three had an unidentified source of exposure. All sequenced viruses were clade 2.3.4.4b. Overall, 62 cases (89%) reported eye redness, 32 (46%) fever and 29 (41%) respiratory symptoms; 54 of 67 cases (81%) reported receiving antiviral treatment. Most illnesses were mild; however, four patients were hospitalized. Of the hospitalized patients, three had pneumonia and one died. No human-to-human transmission was detected. Occupational exposure to infected animals was a risk factor for HPAI A(H5N1) virus infection and the risk to the general population remains low; however, the two cases exposed to infected backyard poultry and three cases with unidentified exposures highlight that ongoing vigilance is warranted. AB - Author manuscript AN - cdc:261228 C4 - PMC12477757 DO - https://doi.org/10.1038/s41591-025-03905-2 IS - 11 J2 - Nature Medicine KW - Adolescent KW - Influenza in Birds KW - Female KW - Animals KW - Aged KW - Young Adult KW - Poultry KW - Cattle KW - Child KW - Risk Factors KW - Male KW - Middle Aged KW - Humans KW - Influenza A Virus, H5N1 Subtype KW - Adult KW - Influenza, Human KW - influenza A virus KW - H5N1 subtype KW - dairy cows KW - poultry KW - disease outbreak KW - epidemiology KW - Humans KW - Influenza, Human KW - Influenza A Virus, H5N1 Subtype KW - Animals KW - Female KW - Male KW - Adult KW - Middle Aged KW - Poultry KW - Aged KW - Influenza in Birds KW - Adolescent KW - Child KW - Young Adult KW - Cattle KW - Risk Factors LA - eng PY - 2025 T2 - Nature Medicine T2 - Nature Medicine, 2025, v. 31, no. 11 TI - Human Infections With Highly Pathogenic Avian Influenza A(H5N1) Viruses in the United States From March 2024 to May 2025. VL - 31 UR - https://stacks.cdc.gov/view/cdc/261228 ER -
Systemic Toxicity Induced by Topical Application of the Sulfonic Acids, Perfluorobutane Sulfonic Acid (PFBS) and Perfluoropentane Sulfonic Acid (PFPeS), in a Murine Model.

Cooper, Madison P. ;

Weatherly, Lisa M.

October 2025 | Toxicology and Applied Pharmacology, 2025, v. 503

Per- and polyfluoroalkyl substances (PFAS) are a large group of synthetic surfactants incorporated into products for their chemical and physical properties. Studies have associated PFAS with adverse health effects. Although there is a high potential for dermal exposure, toxicity studies related to this route of exposure are lacking. The present stu ...

10/09/2026

Supporting Files

Title : Systemic Toxicity Induced by Topical Application of the Sulfonic Acids, Perfluorobutane Sulfonic Acid (PFBS) and Perfluoropentane Sulfonic Acid (PFPeS), in a Murine Model. Personal Author(s) : Cooper, Madison P.;Weatherly, Lisa M.;Lukomska, Ewa;Jackson, Laurel G.;Anderson, Stacey E.; Published Date : October 2025 Pages in Document : 117487 (28 pdf pages) Source : Toxicology and Applied Pharmacology, 2025, v. 503 DOI : https://doi.org/10.1016/j.taap.2025.117487 Journal Title : Toxicology and Applied Pharmacology
Cooper, M. P., Weatherly, L. M., Lukomska, E., Jackson, L. G., & Anderson, S. E. (2025). Systemic Toxicity Induced by Topical Application of the Sulfonic Acids, Perfluorobutane Sulfonic Acid (PFBS) and Perfluoropentane Sulfonic Acid (PFPeS), in a Murine Model. Toxicology and Applied Pharmacology, 503. https://doi.org/10.1016/j.taap.2025.117487

Cooper, Madison P., Lisa M. Weatherly, Ewa Lukomska, Laurel G. Jackson, and Stacey E. Anderson. "Systemic Toxicity Induced by Topical Application of the Sulfonic Acids, Perfluorobutane Sulfonic Acid (PFBS) and Perfluoropentane Sulfonic Acid (PFPeS), in a Murine Model." Toxicology and Applied Pharmacology 503 (2025). https://doi.org/10.1016/j.taap.2025.117487.

Cooper, Madison P., et al. "Systemic Toxicity Induced by Topical Application of the Sulfonic Acids, Perfluorobutane Sulfonic Acid (PFBS) and Perfluoropentane Sulfonic Acid (PFPeS), in a Murine Model." Toxicology and Applied Pharmacology, vol. 503, 2025. Stacks. https://doi.org/10.1016/j.taap.2025.117487.
Export RIS Citation Information. TY - Journal Article AU - Cooper, Madison P. AU - Weatherly, Lisa M. AU - Lukomska, Ewa AU - Jackson, Laurel G. AU - Anderson, Stacey E. AB - Per- and polyfluoroalkyl substances (PFAS) are a large group of synthetic surfactants incorporated into products for their chemical and physical properties. Studies have associated PFAS with adverse health effects. Although there is a high potential for dermal exposure, toxicity studies related to this route of exposure are lacking. The present study evaluated the systemic toxicity following a sub-chronic 28-day dermal exposure to perfluorobutane sulfonic acid (PFBS) (1.25-5 %) or perfluoropentane sulfonic acid (PFPeS) (1.25-5 %) in a murine model. Elevated levels of both PFAS were detected in the serum and urine, suggesting that absorption occurs through the skin. Additionally, both PFAS induced significantly increased relative liver weight, altered serum chemistries, altered skin and liver histopathology, and significantly decreased relative spleen weight (PFPeS only). Gene expression changes were observed in the liver and skin for genes involved in fatty acid metabolism, inflammation, and skin integrity. In general, the PFPeS-induced changes in the endpoints examined were observed more frequently compared to PFBS, supporting the concept that longer-chain PFAS are more toxic. These findings support PFAS absorption through the skin, leading to liver damage and systemic toxicity. AB - Author manuscript AN - cdc:261227 C4 - PMC12360418 DO - https://doi.org/10.1016/j.taap.2025.117487 J2 - Toxicology and Applied Pharmacology KW - Fluorocarbons KW - Skin KW - Spleen KW - Female KW - Administration, Cutaneous KW - Animals KW - Sulfonic Acids KW - Male KW - Organ Size KW - Liver KW - Mice KW - perfluorobutane sulfonic acid (PFBS) KW - perfluoropentane sulfonic acid (PFPeS) KW - toxicity KW - immune KW - dermal KW - liver damage KW - Animals KW - Fluorocarbons KW - Mice KW - Liver KW - Sulfonic Acids KW - Skin KW - Female KW - Male KW - Spleen KW - Administration, Cutaneous KW - Organ Size LA - eng PY - 2025 T2 - Toxicology and Applied Pharmacology T2 - Toxicology and Applied Pharmacology, 2025, v. 503 TI - Systemic Toxicity Induced by Topical Application of the Sulfonic Acids, Perfluorobutane Sulfonic Acid (PFBS) and Perfluoropentane Sulfonic Acid (PFPeS), in a Murine Model. VL - 503 UR - https://stacks.cdc.gov/view/cdc/261227 ER -
Parental Attitudes, Beliefs, and Experiences Related to Pediatric COVID-19 Vaccination.

Kang, Yoonjae ;

Zhang, Fan

August 2025 | Vaccine, 2025, v. 62

To assess parental attitudes, beliefs, and experiences related to pediatric COVID-19 vaccination.An online, national survey of 2005 U.S. parents aged 18 and older was conducted during August 17-25, 2023. Parental attitudes and beliefs about pediatric COVID-19 vaccination, receipt of a COVID-19 vaccination recommendation for their child, and reasons ...

10/09/2026

Supporting Files

Title : Parental Attitudes, Beliefs, and Experiences Related to Pediatric COVID-19 Vaccination. Personal Author(s) : Kang, Yoonjae;Zhang, Fan;Vogt, Tara M; Published Date : August 2025 Pages in Document : 127043 (17 pdf pages) Source : Vaccine, 2025, v. 62 DOI : https://doi.org/10.1016/j.vaccine.2025.127043 Journal Title : Vaccine
Kang, Y., Zhang, F., & Vogt, T. M. (2025). Parental Attitudes, Beliefs, and Experiences Related to Pediatric COVID-19 Vaccination. Vaccine, 62. https://doi.org/10.1016/j.vaccine.2025.127043

Kang, Yoonjae, Fan Zhang, and Tara M Vogt. "Parental Attitudes, Beliefs, and Experiences Related to Pediatric COVID-19 Vaccination." Vaccine 62 (2025). https://doi.org/10.1016/j.vaccine.2025.127043.

Kang, Yoonjae, et al. "Parental Attitudes, Beliefs, and Experiences Related to Pediatric COVID-19 Vaccination." Vaccine, vol. 62, 2025. Stacks. https://doi.org/10.1016/j.vaccine.2025.127043.
Export RIS Citation Information. TY - Journal Article AU - Kang, Yoonjae AU - Zhang, Fan AU - Vogt, Tara M AB - To assess parental attitudes, beliefs, and experiences related to pediatric COVID-19 vaccination. AB - An online, national survey of 2005 U.S. parents aged 18 and older was conducted during August 17-25, 2023. Parental attitudes and beliefs about pediatric COVID-19 vaccination, receipt of a COVID-19 vaccination recommendation for their child, and reasons for not getting their child vaccinated against COVID-19 were assessed. Factors associated with child's COVID-19 vaccination were also assessed. AB - Less than half (46.1 %) of responding parents strongly or somewhat agreed that COVID-19 vaccine is generally safe for children; agreement was higher among parents of 12-17-year-olds (54.2 %) vs. 0-4-year-olds (35.4 %), children with private (52.8 %) vs. Medicaid/CHIP health insurance (41.0 %), and those living in urban (54.2 %) vs. rural areas (29.8 %) (p-values<0.0001). Approximately 60 % of parents reported that their child's health care provider (HCP) recommended COVID-19 vaccination for their child, with higher proportions reporting a recommendation among those with 12-17-year-olds (73.1 %) vs. 0-4-year-olds (43.1 %) (p-value<0.0001), children with private (65.6 %) vs. Medicaid/CHIP health insurance (58.2 %) (p-value = 0.0013), and those living in urban (67.3 %) vs. rural areas (51.6 %) (p-value<0.0001). The top three reported reasons for not getting their child vaccinated against COVID-19 were 1) worry about serious/unknown long-term health problems from the vaccine (52.8 %), 2) a belief that COVID-19 vaccination is not effective at preventing COVID-19 (36.3 %), and 3) child/family has already had COVID-19 (19.3 %). Parents who had received COVID-19 vaccine themselves were more likely to vaccinate their child against COVID-19 (received bivalent vaccine dose: OR = 25.8 [15.9, 41.7]; received at least one dose, but not bivalent vaccine dose: OR = 11.1 [6.8, 18.2]). AB - Parental concerns around serious/unknown long-term health problems related to COVID-19 vaccination were observed. In addition, a significant proportion of parents reported not having received a COVID-19 vaccination recommendation. Addressing parents' concerns regarding vaccine safety remains important, especially in rural areas. AB - Author manuscript AN - cdc:261226 C4 - PMC12448224 DO - https://doi.org/10.1016/j.vaccine.2025.127043 J2 - Vaccine KW - Adolescent KW - Health Knowledge, Attitudes, Practice KW - Female KW - Vaccination KW - Parents KW - SARS-CoV-2 KW - Young Adult KW - COVID-19 KW - Infant, Newborn KW - Vaccination Hesitancy KW - Child KW - Surveys and Questionnaires KW - COVID-19 Vaccines KW - Infant KW - Male KW - Humans KW - Middle Aged KW - Child, Preschool KW - Adult KW - pediatric COVID-19 vaccination KW - parental vaccination attitudes/beliefs KW - COVID-19 vaccination KW - Humans KW - Parents KW - Child KW - COVID-19 Vaccines KW - COVID-19 KW - Adolescent KW - Male KW - Female KW - Child, Preschool KW - Health Knowledge, Attitudes, Practice KW - Vaccination KW - Adult KW - Infant KW - Surveys and Questionnaires KW - Young Adult KW - SARS-CoV-2 KW - Middle Aged KW - Vaccination Hesitancy KW - Infant, Newborn LA - eng PY - 2025 T2 - Vaccine T2 - Vaccine, 2025, v. 62 TI - Parental Attitudes, Beliefs, and Experiences Related to Pediatric COVID-19 Vaccination. VL - 62 UR - https://stacks.cdc.gov/view/cdc/261226 ER -
Where do Children Get Vaccinated in the U.S.? Parental Experiences, Attitudes, and Beliefs About Place of Vaccination With a Focus on Pharmacies and Schools.

Kang, Yoonjae ;

Zhang, Fan

August 2025 | Vaccine, 2025, v. 62

To assess parental experiences, attitudes, and beliefs about place of pediatric vaccination in the U.S. with a focus on pharmacies and schools.An online, national survey of 2005 U.S. parents ages 18 years and older was conducted during August 17-25, 2023. Topics included 1) places their children 17 years of age and under had ever been vaccinated, 2 ...

10/09/2026

Supporting Files

Title : Where do Children Get Vaccinated in the U.S.? Parental Experiences, Attitudes, and Beliefs About Place of Vaccination With a Focus on Pharmacies and Schools. Personal Author(s) : Kang, Yoonjae;Zhang, Fan;Vogt, Tara M; Published Date : August 2025 Pages in Document : 126801 (15 pdf pages) Source : Vaccine, 2025, v. 62 DOI : https://doi.org/10.1016/j.vaccine.2025.126801 Journal Title : Vaccine
Kang, Y., Zhang, F., & Vogt, T. M. (2025). Where do Children Get Vaccinated in the U.S.? Parental Experiences, Attitudes, and Beliefs About Place of Vaccination With a Focus on Pharmacies and Schools. Vaccine, 62. https://doi.org/10.1016/j.vaccine.2025.126801

Kang, Yoonjae, Fan Zhang, and Tara M Vogt. "Where do Children Get Vaccinated in the U.S.? Parental Experiences, Attitudes, and Beliefs About Place of Vaccination With a Focus on Pharmacies and Schools." Vaccine 62 (2025). https://doi.org/10.1016/j.vaccine.2025.126801.

Kang, Yoonjae, et al. "Where do Children Get Vaccinated in the U.S.? Parental Experiences, Attitudes, and Beliefs About Place of Vaccination With a Focus on Pharmacies and Schools." Vaccine, vol. 62, 2025. Stacks. https://doi.org/10.1016/j.vaccine.2025.126801.
Export RIS Citation Information. TY - Journal Article AU - Kang, Yoonjae AU - Zhang, Fan AU - Vogt, Tara M AB - To assess parental experiences, attitudes, and beliefs about place of pediatric vaccination in the U.S. with a focus on pharmacies and schools. AB - An online, national survey of 2005 U.S. parents ages 18 years and older was conducted during August 17-25, 2023. Topics included 1) places their children 17 years of age and under had ever been vaccinated, 2) places parents feel comfortable taking their child for vaccination, and 3) parental attitudes, beliefs, and experiences related to vaccination of their child at a pharmacy or school. If the parent had more than one child, the survey randomly selected a reference child. AB - The most frequently reported place of pediatric vaccination was a doctor's office (75.8 %), clinic or health center (23.1 %), and hospital (19.1 %). A smaller proportion of parents reported getting their child vaccinated at a pharmacy (15.9 %), health department clinic (9.8 %), or school (6.6 %). Vaccination at a pharmacy was more commonly reported by parents of 12-17-year-olds (22.9 %) vs. 0-4-year-olds (5.7 %) (p-value<0.0001), those living in urban (16.3 %) vs. rural areas (11.1 %) (p-value = 0.0182), and children with private (20.0 %) vs. public (Medicaid/CHIP) health insurance (12.4 %) (p-value<0.0001). Vaccination at a school was more commonly reported by parents of 12-17-year-olds (9.0 %) vs. 0-4-year-olds (3.2 %) (p-value = 0.0002). Among parents who reported getting their child vaccinated at a pharmacy (n = 318), 92.2 % rated their overall satisfaction level 'very good' or 'good.' Among parents whose children have gotten vaccinated at school (n = 124), 83.9 % reported their overall satisfaction level to be 'very good' or 'good.' AB - While most children receive their vaccination at a doctor's office, parents who have experience getting their child vaccinated in alternative places of vaccination, such as pharmacies and schools, reported a positive overall satisfaction level. Pharmacy and school vaccination may be acceptable, especially for older children and adolescents. AB - Author manuscript AN - cdc:261225 C4 - PMC12321230 DO - https://doi.org/10.1016/j.vaccine.2025.126801 J2 - Vaccine KW - Adolescent KW - Schools KW - Health Knowledge, Attitudes, Practice KW - Female KW - Vaccination KW - Pharmacies KW - Parents KW - Young Adult KW - Child KW - Surveys and Questionnaires KW - Male KW - Middle Aged KW - Humans KW - Adult KW - pediatric vaccination KW - place of vaccination KW - parental vaccination attitudes KW - attitudes about pharmacy vaccination KW - attitudes about school vaccination KW - Humans KW - Parents KW - Adolescent KW - Schools KW - Female KW - Male KW - Vaccination KW - Child KW - Pharmacies KW - Health Knowledge, Attitudes, Practice KW - Adult KW - Surveys and Questionnaires KW - Middle Aged KW - Young Adult LA - eng PY - 2025 T2 - Vaccine T2 - Vaccine, 2025, v. 62 TI - Where do Children Get Vaccinated in the U.S.? Parental Experiences, Attitudes, and Beliefs About Place of Vaccination With a Focus on Pharmacies and Schools. VL - 62 UR - https://stacks.cdc.gov/view/cdc/261225 ER -
Patterns of Yeast Infections and Antifungal Use in the First Trimester of Pregnancy: Findings From the Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019.

Papadopoulos, Eleni A. ;

Howley, Meredith M.

October 2025 | Journal of Women'S Health (2002), 2025, v. 34, no. 10

Yeast infections are common during pregnancy. Understanding their current prevalence and corresponding treatments during pregnancy is important. We used data from a U.S. population-based retrospective study of recently pregnant people to describe patterns of first trimester maternal yeast infections and antifungal use.Using a cohort of control part ...

10/09/2026

Supporting Files

Title : Patterns of Yeast Infections and Antifungal Use in the First Trimester of Pregnancy: Findings From the Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019. Personal Author(s) : Papadopoulos, Eleni A.;Howley, Meredith M.;Fisher, Sarah C.;Werler, Martha M.;Romitti, Paul A.;Browne, Marilyn L.; Published Date : October 2025 Pages in Document : 1232-1239 (16 pdf pages) Source : Journal of Women'S Health (2002), 2025, v. 34, no. 10 DOI : https://doi.org/10.1177/15409996251363394 Journal Title : Journal of Women'S Health (2002)
Papadopoulos, E. A., Howley, M. M., Fisher, S. C., Werler, M. M., Romitti, P. A., & Browne, M. L. (2025). Patterns of Yeast Infections and Antifungal Use in the First Trimester of Pregnancy: Findings From the Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019. Journal of Women'S Health (2002), 34(10). https://doi.org/10.1177/15409996251363394

Papadopoulos, Eleni A., Meredith M. Howley, Sarah C. Fisher, Martha M. Werler, Paul A. Romitti, and Marilyn L. Browne. "Patterns of Yeast Infections and Antifungal Use in the First Trimester of Pregnancy: Findings From the Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019." Journal of Women'S Health (2002) 34, no. 10 (2025). https://doi.org/10.1177/15409996251363394.

Papadopoulos, Eleni A., et al. "Patterns of Yeast Infections and Antifungal Use in the First Trimester of Pregnancy: Findings From the Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019." Journal of Women'S Health (2002), vol. 34, no. 10, 2025. Stacks. https://doi.org/10.1177/15409996251363394.
Export RIS Citation Information. TY - Journal Article AU - Papadopoulos, Eleni A. AU - Howley, Meredith M. AU - Fisher, Sarah C. AU - Werler, Martha M. AU - Romitti, Paul A. AU - Browne, Marilyn L. AB - Yeast infections are common during pregnancy. Understanding their current prevalence and corresponding treatments during pregnancy is important. We used data from a U.S. population-based retrospective study of recently pregnant people to describe patterns of first trimester maternal yeast infections and antifungal use. AB - Using a cohort of control participants from the Birth Defects Study to Evaluate Pregnancy exposureS, self-reports of first trimester yeast infections and antifungal use were collected via computer-assisted telephone interviews for births during 2014-2019. We described maternal characteristics and examined the prevalence of yeast infections and antifungal use overall and by study site and birth year. Tests for trend were used to evaluate changes over the study period. AB - After exclusions, there were 1,524 control participants included in our sample. First trimester yeast infections (9.8%) and antifungal use (8.6%) were common. More participants reported prescription (52.7%) than over-the-counter (45.0%) antifungals; most users reported a topical antifungal (72.5%). Prevalence of yeast infections and antifungal use increased modestly, but nonsignificantly, over the study period, ranging from 7.8% to 10.9% for yeast infections and 7.2% to 9.8% for antifungal use. Prevalence of topical and over-the-counter antifungals significantly increased over the study period; use of oral and prescription antifungals modestly decreased. AB - In our cohort, first trimester yeast infections and antifungal use were relatively common and modestly increased throughout the study period, although this trend was not significant. We observed significant increases for topical and over-the-counter antifungals. Additional research is needed to investigate the reasons behind these prevalence changes. AB - Author manuscript AN - cdc:261224 C4 - PMC13098719 DO - https://doi.org/10.1177/15409996251363394 IS - 10 J2 - Journal of Women'S Health (2002) KW - Pregnancy Complications, Infectious KW - Pregnancy KW - Retrospective Studies KW - Female KW - Prevalence KW - Mycoses KW - Humans KW - Young Adult KW - Antifungal Agents KW - Pregnancy Trimester, First KW - Adult KW - pregnancy KW - antifungal KW - yeast infection KW - Birth Defects Study to Evaluate Pregnancy exposureS KW - Humans KW - Female KW - Pregnancy KW - Pregnancy Trimester, First KW - Antifungal Agents KW - Adult KW - Retrospective Studies KW - Pregnancy Complications, Infectious KW - Prevalence KW - Mycoses KW - Young Adult LA - eng PY - 2025 T2 - Journal of Women'S Health (2002) T2 - Journal of Women'S Health (2002), 2025, v. 34, no. 10 TI - Patterns of Yeast Infections and Antifungal Use in the First Trimester of Pregnancy: Findings From the Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019. VL - 34 UR - https://stacks.cdc.gov/view/cdc/261224 ER -
Microbiota and Kidney Disease: the Road Ahead.

Bloom, Patricia P. ;

Garrett, Wendy S.

October 2025 | Nature Reviews. Nephrology, 2025, v. 21, no. 10

More than 850 million individuals worldwide, accounting for 10-15% of the adult population, are estimated to have chronic kidney disease. Each of these individuals is host to tens of trillions of microorganisms that are collectively referred to as microbiota - a dynamic ecosystem that both influences host health and is itself influenced by changes ...

10/09/2026

Supporting Files

Title : Microbiota and Kidney Disease: the Road Ahead. Personal Author(s) : Bloom, Patricia P.;Garrett, Wendy S.;Penniston, Kristina L.;Winkler, Mari-Karoliina H.;Hazen, Stanley L.;Agudelo, Jose;Suryavanshi, Mangesh;Babiker, Ahmed;Dodd, Dylan;Fischbach, Michael A.;Huang, Kerwyn Casey;Huttenhower, Curtis;Joe, Bina;Kalantar-Zadeh, Kamyar;Knight, Rob;Miller, Aaron W.;Rabb, Hamid;Srivastava, Anvesha;Wilson Tang, W. H.;Turnbaugh, Peter J.;Walker, Alan W.;Wilck, Nicola;Xu, Jiaojiao;Yang, Tao;Himmelfarb, Jonathan;Redinbo, Matthew R.;Wu, Gary D.;Woodworth, Michael H.;Ackerman, A. Lenore;Winter, Sebastian;Rinschen, Markus M.;Hassan, Hatim A.;Biruete, Annabel;Anderson, Amanda H.;Pluznick, Jennifer L.; Published Date : October 2025 Pages in Document : 702-716 (37 pdf pages) Source : Nature Reviews. Nephrology, 2025, v. 21, no. 10 DOI : https://doi.org/10.1038/s41581-025-00988-5 Journal Title : Nature Reviews. Nephrology
Bloom, P. P., Garrett, W. S., Penniston, K. L., Winkler, M. K. H., Hazen, S. L., Agudelo, J., Suryavanshi, M., Babiker, A., Dodd, D., Fischbach, M. A., Huang, K. C., Huttenhower, C., Joe, B., Kalantar-Zadeh, K., Knight, R., Miller, A. W., Rabb, H., Srivastava, A., Wilson Tang, W. H., ... Pluznick, J. L. (2025). Microbiota and Kidney Disease: the Road Ahead. Nature Reviews. Nephrology, 21(10). https://doi.org/10.1038/s41581-025-00988-5

Bloom, Patricia P., Wendy S. Garrett, Kristina L. Penniston, Mari-Karoliina H. Winkler, Stanley L. Hazen, Jose Agudelo, and Mangesh Suryavanshi, et al.. "Microbiota and Kidney Disease: the Road Ahead." Nature Reviews. Nephrology 21, no. 10 (2025). https://doi.org/10.1038/s41581-025-00988-5.

Bloom, Patricia P., et al. "Microbiota and Kidney Disease: the Road Ahead." Nature Reviews. Nephrology, vol. 21, no. 10, 2025. Stacks. https://doi.org/10.1038/s41581-025-00988-5.
Export RIS Citation Information. TY - Journal Article AU - Bloom, Patricia P. AU - Garrett, Wendy S. AU - Penniston, Kristina L. AU - Winkler, Mari-Karoliina H. AU - Hazen, Stanley L. AU - Agudelo, Jose AU - Suryavanshi, Mangesh AU - Babiker, Ahmed AU - Dodd, Dylan AU - Fischbach, Michael A. AU - Huang, Kerwyn Casey AU - Huttenhower, Curtis AU - Joe, Bina AU - Kalantar-Zadeh, Kamyar AU - Knight, Rob AU - Miller, Aaron W. AU - Rabb, Hamid AU - Srivastava, Anvesha AU - Wilson Tang, W. H. AU - Turnbaugh, Peter J. AU - Walker, Alan W. AU - Wilck, Nicola AU - Xu, Jiaojiao AU - Yang, Tao AU - Himmelfarb, Jonathan AU - Redinbo, Matthew R. AU - Wu, Gary D. AU - Woodworth, Michael H. AU - Ackerman, A. Lenore AU - Winter, Sebastian AU - Rinschen, Markus M. AU - Hassan, Hatim A. AU - Biruete, Annabel AU - Anderson, Amanda H. AU - Pluznick, Jennifer L. AB - More than 850 million individuals worldwide, accounting for 10-15% of the adult population, are estimated to have chronic kidney disease. Each of these individuals is host to tens of trillions of microorganisms that are collectively referred to as microbiota - a dynamic ecosystem that both influences host health and is itself influenced by changes in the host. Available evidence supports the existence of functional connections between resident microorganisms and kidney health that are altered in the context of specific kidney diseases, including acute kidney injury, chronic kidney disease and renal stone disease. Moreover, promising data from preclinical studies suggest that targeting of gut microbial pathways may provide new therapeutic opportunities for the treatment of kidney disease. This Roadmap describes current understanding of the mechanisms by which microorganisms regulate host organ function, the effects of kidney disease on the gut microbiome, and how these insights may contribute to the development of microbe-targeted therapeutics. We highlight key knowledge gaps that remain to be addressed and strategies for addressing these, outlining both the promise and the potential pitfalls of leveraging our understanding of the gut microbiota to better understand and treat kidney disease. AB - Author manuscript AN - cdc:261223 C4 - PMC12434838 DO - https://doi.org/10.1038/s41581-025-00988-5 IS - 10 J2 - Nature Reviews. Nephrology KW - Kidney Diseases KW - Gastrointestinal Microbiome KW - Acute Kidney Injury KW - Renal Insufficiency, Chronic KW - Microbiota KW - Humans KW - Humans KW - Gastrointestinal Microbiome KW - Kidney Diseases KW - Renal Insufficiency, Chronic KW - Acute Kidney Injury KW - Microbiota LA - eng PY - 2025 T2 - Nature Reviews. Nephrology T2 - Nature Reviews. Nephrology, 2025, v. 21, no. 10 TI - Microbiota and Kidney Disease: the Road Ahead. VL - 21 UR - https://stacks.cdc.gov/view/cdc/261223 ER -
Driving Safety Among Adolescents With Health Conditions: an Integrative Review.

DiFusco, Leigh Ann ;

Liu, Xiaoxuan (Priscilla)

June 2025 | Journal of Transport & Health, 2025, v. 42

Obtaining a driver's license enhances independence and quality of life but can be challenging for adolescents with health conditions. Health conditions may impact driving behavior and not always require driving restrictions. Strategies that promote safe independent driving for adolescents with various health conditions are not well described.The go ...

10/09/2026

Supporting Files

Title : Driving Safety Among Adolescents With Health Conditions: an Integrative Review. Personal Author(s) : DiFusco, Leigh Ann;Liu, Xiaoxuan (Priscilla);Curry, Allison E.;McDonald, Catherine C.; Published Date : June 2025 Pages in Document : 102040(31 pdf pages) Source : Journal of Transport & Health, 2025, v. 42 DOI : https://doi.org/10.1016/j.jth.2025.102040 Journal Title : Journal of Transport & Health
DiFusco, L. A., Liu, X. (., Curry, A. E., & McDonald, C. C. (2025). Driving Safety Among Adolescents With Health Conditions: an Integrative Review. Journal of Transport & Health, 42. https://doi.org/10.1016/j.jth.2025.102040

DiFusco, Leigh Ann, Xiaoxuan (Priscilla) Liu, Allison E. Curry, and Catherine C. McDonald. "Driving Safety Among Adolescents With Health Conditions: an Integrative Review." Journal of Transport & Health 42 (2025). https://doi.org/10.1016/j.jth.2025.102040.

DiFusco, Leigh Ann, et al. "Driving Safety Among Adolescents With Health Conditions: an Integrative Review." Journal of Transport & Health, vol. 42, 2025. Stacks. https://doi.org/10.1016/j.jth.2025.102040.
Export RIS Citation Information. TY - Journal Article AU - DiFusco, Leigh Ann AU - Liu, Xiaoxuan (Priscilla) AU - Curry, Allison E. AU - McDonald, Catherine C. AB - Obtaining a driver's license enhances independence and quality of life but can be challenging for adolescents with health conditions. Health conditions may impact driving behavior and not always require driving restrictions. Strategies that promote safe independent driving for adolescents with various health conditions are not well described. AB - The goal of this integrative review was to summarize the body of literature about safe driving behaviors and strategies to promote positive driving experiences among adolescents (15-24 years old) with at least one of the following health conditions: attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), disruptive behavior/conduct disorder, type 1 diabetes (TID), congenital heart disease (CHD), epilepsy/seizure disorder, neurological/neurobehavioral conditions, obstructive sleep apnea (OSA), restless leg syndrome (RLS), narcolepsy, and mental health conditions. AB - Sixty-eight studies published between 2007 and 2024 were included in the review. Over 70% of the included studies focused on ADHD and/or ASD. Driving attitudes, driving behavior/performance, licensure processes, driving interventions and other driving-related factors emerged as key outcome themes. Older age at licensure was common among the included sample. Evidence consistently showed that adolescents with ADHD, ASD, traumatic brain injury, developmental coordination disorders, and mood disorders experienced more unsafe driving compared to their age-matched peers. Blood glucose management was a common concern in studies examining driving behaviors among adolescents with T1D. Studies among adolescents with ADHD and ASD using well-developed interventions may serve as a model for future research examining the impact of other health conditions on driving behaviors. AB - Our findings substantiate the body of research devoted to understanding safe independent driving among adolescents with ADHD and ASD and reveal opportunities for more research among adolescents with disruptive behavior/conduct disorder, T1D, CHD, epilepsy/seizure disorder, neurological/neurobehavioral conditions, OSA, RLS, narcolepsy and mental health conditions to inform health policies and clinical practice. AB - Author manuscript AN - cdc:261222 C4 - PMC12290920 DO - https://doi.org/10.1016/j.jth.2025.102040 J2 - Journal of Transport & Health KW - Adolescent KW - Automobile Driving KW - Quality of Life KW - Adolescent KW - Quality of Life KW - Automobile Driving LA - eng PY - 2025 T2 - Journal of Transport & Health T2 - Journal of Transport & Health, 2025, v. 42 TI - Driving Safety Among Adolescents With Health Conditions: an Integrative Review. VL - 42 UR - https://stacks.cdc.gov/view/cdc/261222 ER -
Assessing Early Impact of the Hear Her® Communication Campaign.

Spencer, Patricia ;

Ouyang, Lijing

July 2025 | Health Promotion Practice, July 2025

The Hear Her communication campaign was launched nationally in August 2020 to raise awareness of urgent maternal warning signs during and after pregnancy and improve communication between patients and their health care providers. To assess aided campaign awareness during early implementation, an internet panel survey was conducted a month after the ...

10/09/2026

Supporting Files

Title : Assessing Early Impact of the Hear Her® Communication Campaign. Personal Author(s) : Spencer, Patricia;Ouyang, Lijing;Cox, Shanna;Tevendale, Heather;Carrigan, Sarah;Behm, Brittany;Rosenthal, Jacqueline;Thompson, Ashley E.;Lakusta, Mike;Strunz, Eric;Barfield, Wanda D.; Published Date : July 2025 Pages in Document : 20 pdf pages Source : Health Promotion Practice, July 2025 DOI : https://doi.org/10.1177/15248399251354966 Journal Title : Health Promotion Practice
Spencer, P., Ouyang, L., Cox, S., Tevendale, H., Carrigan, S., Behm, B., Rosenthal, J., Thompson, A. E., Lakusta, M., Strunz, E., & Barfield, W. D. (2025). Assessing Early Impact of the Hear Her® Communication Campaign. Health Promotion Practice. https://doi.org/10.1177/15248399251354966

Spencer, Patricia, Lijing Ouyang, Shanna Cox, Heather Tevendale, Sarah Carrigan, Brittany Behm, and Jacqueline Rosenthal, et al.. "Assessing Early Impact of the Hear Her® Communication Campaign." Health Promotion Practice (2025). https://doi.org/10.1177/15248399251354966.

Spencer, Patricia, et al. "Assessing Early Impact of the Hear Her® Communication Campaign." Health Promotion Practice, 2025. Stacks. https://doi.org/10.1177/15248399251354966.
Export RIS Citation Information. TY - Journal Article AU - Spencer, Patricia AU - Ouyang, Lijing AU - Cox, Shanna AU - Tevendale, Heather AU - Carrigan, Sarah AU - Behm, Brittany AU - Rosenthal, Jacqueline AU - Thompson, Ashley E. AU - Lakusta, Mike AU - Strunz, Eric AU - Barfield, Wanda D. AB - The Hear Her communication campaign was launched nationally in August 2020 to raise awareness of urgent maternal warning signs during and after pregnancy and improve communication between patients and their health care providers. To assess aided campaign awareness during early implementation, an internet panel survey was conducted a month after the campaign launch (Wave 1) with a follow-up survey 7 months later (Wave 2). The survey was fielded nationwide with enhanced recruitment for respondents in the campaign's priority markets: Atlanta, Dallas, New Orleans, New York, and St. Louis. Aided campaign awareness increased 14.2 percentage points overall among pregnant and postpartum survey participants between waves, with the highest increase in awareness among non-Hispanic Black pregnant and postpartum survey participants (19.8 percentage points). Among Wave 2 survey respondents, those aware of the campaign were more likely to search for information when something did not feel right (adjusted prevalence ratio [aPR] = 1.05), discuss concerns with someone close (aPR = 1.14), or desire more information from their health care provider on pregnancy-related complications or warning signs and symptoms (aPR = 1.62)-after adjustment for age, race/ethnicity, education, geographical location (residence in campaign's priority markets for media buys), and household income. These findings suggest that aided awareness of the Hear Her campaign increased among pregnant and postpartum survey participants in the first 7 months of the campaign and was associated with outcomes the campaign may influence. This study provides considerations for measuring outcomes associated with implementation of Hear Her and similar campaigns. AB - Author manuscript AN - cdc:261221 C4 - PMC12989970 DO - https://doi.org/10.1177/15248399251354966 J2 - Health Promotion Practice KW - Pregnancy KW - Ethnicity KW - Surveys and Questionnaires KW - Female KW - Internet KW - Communication KW - Infant KW - Follow-Up Studies KW - Prevalence KW - Postpartum Period KW - Humans KW - Health Personnel KW - Hear Her KW - pregnancy-related complications KW - postpartum KW - media campaigns KW - communication campaigns KW - maternal mortality KW - Humans KW - Female KW - Pregnancy KW - Infant KW - Ethnicity KW - Follow-Up Studies KW - Prevalence KW - Health Personnel KW - Communication KW - Surveys and Questionnaires KW - Postpartum Period KW - Internet LA - eng PY - 2025 T2 - Health Promotion Practice T2 - Health Promotion Practice, July 2025 TI - Assessing Early Impact of the Hear Her® Communication Campaign. UR - https://stacks.cdc.gov/view/cdc/261221 ER -
A Review of Reports to CDC of Travelers Who Flew While Infectious With Pertussis From April 2013 to February 2024.

Pringle, Kristen ;

Clark, Robert Mason

December 3, 2025 | Journal of Public Health Management and Practice : JPHMP, 2025, v. 31, no. 6

Pertussis is endemic worldwide, and exposure can occur anywhere, including commercial aircraft. Travelers exposed to an infectious person with pertussis may receive post-exposure prophylaxis (PEP) for up to 21 days after exposure to decrease risk of infection. This is accomplished through the identification of infectious travelers and their aircraf ...

10/09/2026

Supporting Files

Title : A Review of Reports to CDC of Travelers Who Flew While Infectious With Pertussis From April 2013 to February 2024. Personal Author(s) : Pringle, Kristen;Clark, Robert Mason;Fowler, Jennifer J.;Gearhart, Shannon L.;Hausman, Leslie;Rearden, Paisley;Walker, Grayson K.;Kinzer, Michael;Preston, Leigh Ellyn;Brown, Clive;Mase, Sundari;Gertz, Alida M.; Published Date : December 3, 2025 Pages in Document : 957-961 (10 pdf pages) Source : Journal of Public Health Management and Practice : JPHMP, 2025, v. 31, no. 6 DOI : https://doi.org/10.1097/PHH.0000000000002197 Journal Title : Journal of Public Health Management and Practice : JPHMP
Pringle, K., Clark, R. M., Fowler, J. J., Gearhart, S. L., Hausman, L., Rearden, P., Walker, G. K., Kinzer, M., Preston, L. E., Brown, C., Mase, S., & Gertz, A. M. (2025). A Review of Reports to CDC of Travelers Who Flew While Infectious With Pertussis From April 2013 to February 2024. Journal of Public Health Management and Practice : JPHMP, 31(6). https://doi.org/10.1097/PHH.0000000000002197

Pringle, Kristen, Robert Mason Clark, Jennifer J. Fowler, Shannon L. Gearhart, Leslie Hausman, Paisley Rearden, and Grayson K. Walker, et al.. "A Review of Reports to CDC of Travelers Who Flew While Infectious With Pertussis From April 2013 to February 2024." Journal of Public Health Management and Practice : JPHMP 31, no. 6 (2025). https://doi.org/10.1097/PHH.0000000000002197.

Pringle, Kristen, et al. "A Review of Reports to CDC of Travelers Who Flew While Infectious With Pertussis From April 2013 to February 2024." Journal of Public Health Management and Practice : JPHMP, vol. 31, no. 6, 2025. Stacks. https://doi.org/10.1097/PHH.0000000000002197.
Export RIS Citation Information. TY - Journal Article AU - Pringle, Kristen AU - Clark, Robert Mason AU - Fowler, Jennifer J. AU - Gearhart, Shannon L. AU - Hausman, Leslie AU - Rearden, Paisley AU - Walker, Grayson K. AU - Kinzer, Michael AU - Preston, Leigh Ellyn AU - Brown, Clive AU - Mase, Sundari AU - Gertz, Alida M. AB - Pertussis is endemic worldwide, and exposure can occur anywhere, including commercial aircraft. Travelers exposed to an infectious person with pertussis may receive post-exposure prophylaxis (PEP) for up to 21 days after exposure to decrease risk of infection. This is accomplished through the identification of infectious travelers and their aircraft contacts (a process called aircraft contact investigation [Air CIs]). AB - Describe travelers reported to the US Centers for Disease Control and Prevention (CDC) who flew while infectious with pertussis and outcomes of associated Air CIs. AB - CDC's Port Health Activity Reporting System (PHARS) was queried to identify reports of travelers who flew with pertussis from April 12, 2013, to February 28, 2024. AB - Index cases (passengers or crew members) with pertussis who traveled on commercial aircraft and their exposed passenger contacts. AB - Traveler demographics, flight characteristics, outcome data from Air CIs. AB - Three hundred and eight individuals who recently traveled on commercial aircraft with pertussis were identified. Of the passengers determined to be infectious on the flights, Air CIs were initiated for 102/270 (38%) travelers who flew on 163/500 (33%) flights. Among the 337/500 (67%) flights for which Air CI was not initiated, the most common reason was that the index case was seated adjacent to only household members (142/337, 42%). For flights in which Air CIs were initiated, 234 contacts were identified, and one secondary case in a non-household passenger contact was reported. The average time from when contacts were exposed during the flight to when a health department reported the index case to CDC was 11.6 days (median 10.3 days, range: 0-39 days). AB - Timely reporting of pertussis cases after air travel may decrease transmission risk to passenger contacts and prevent severe illness. AB - Author manuscript AN - cdc:261220 C4 - PMC12673511 DO - https://doi.org/10.1097/PHH.0000000000002197 IS - 6 J2 - Journal of Public Health Management and Practice : JPHMP KW - Adolescent KW - Female KW - Aircraft KW - Contact Tracing KW - Whooping Cough KW - Child KW - Male KW - Humans KW - Middle Aged KW - Child, Preschool KW - Adult KW - Travel KW - Centers for Disease Control and Prevention, U.S. KW - aircraft KW - air travel KW - infectious KW - pertussis KW - transmission KW - Humans KW - Whooping Cough KW - Centers for Disease Control and Prevention, U.S. KW - Male KW - Travel KW - Female KW - Adult KW - Middle Aged KW - Adolescent KW - Child KW - Contact Tracing KW - Child, Preschool KW - Aircraft LA - eng PY - 2025 T2 - Journal of Public Health Management and Practice : JPHMP T2 - Journal of Public Health Management and Practice : JPHMP, 2025, v. 31, no. 6 TI - A Review of Reports to CDC of Travelers Who Flew While Infectious With Pertussis From April 2013 to February 2024. VL - 31 UR - https://stacks.cdc.gov/view/cdc/261220 ER -
It is a Good Idea, But Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening.

Brenner, Alison T. ;

Odebunmi, Olufeyisayo O.

October 2025 | Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 2025, v. 34, no. 10

Accessibility, expanding scope of practice, and a rapidly changing policy landscape make US community pharmacies a promising delivery setting for colorectal cancer screening. It is not clear, however, whether community pharmacists are willing to incorporate colorectal cancer screening into their pharmacy practice, what potential drivers of willingn ...

10/09/2026

Supporting Files

Title : It is a Good Idea, But Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening. Personal Author(s) : Brenner, Alison T.;Odebunmi, Olufeyisayo O.;Waters, Austin R.;Wangen, Mary;Marciniak, Macary W.;Ferrari, Renée M.;Wheeler, Stephanie B.;Shah, Parth D.; Published Date : October 2025 Pages in Document : 1820-1827 (19 pdf pages) Source : Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 2025, v. 34, no. 10 DOI : https://doi.org/10.1158/1055-9965.EPI-25-0275 Journal Title : Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology
Brenner, A. T., Odebunmi, O. O., Waters, A. R., Wangen, M., Marciniak, M. W., Ferrari, R. M., Wheeler, S. B., & Shah, P. D. (2025). It is a Good Idea, But Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening. Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 34(10). https://doi.org/10.1158/1055-9965.EPI-25-0275

Brenner, Alison T., Olufeyisayo O. Odebunmi, Austin R. Waters, Mary Wangen, Macary W. Marciniak, Renée M. Ferrari, Stephanie B. Wheeler, and Parth D. Shah. "It is a Good Idea, But Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening." Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology 34, no. 10 (2025). https://doi.org/10.1158/1055-9965.EPI-25-0275.

Brenner, Alison T., et al. "It is a Good Idea, But Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening." Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 34, no. 10, 2025. Stacks. https://doi.org/10.1158/1055-9965.EPI-25-0275.
Export RIS Citation Information. TY - Journal Article AU - Brenner, Alison T. AU - Odebunmi, Olufeyisayo O. AU - Waters, Austin R. AU - Wangen, Mary AU - Marciniak, Macary W. AU - Ferrari, Renée M. AU - Wheeler, Stephanie B. AU - Shah, Parth D. AB - Accessibility, expanding scope of practice, and a rapidly changing policy landscape make US community pharmacies a promising delivery setting for colorectal cancer screening. It is not clear, however, whether community pharmacists are willing to incorporate colorectal cancer screening into their pharmacy practice, what potential drivers of willingness are, and, if unwilling, under what conditions pharmacists would be willing to provide PharmFIT. AB - From September 2022 to January 2023, we surveyed 578 currently practicing community pharmacists. We assessed willingness to provide a pharmacy-based colorectal cancer screening program (PharmFIT). We used multiple linear regression to identify correlates of perceived implementation complexity and multiple logistic regression to explore overall willingness to implement PharmFIT. AB - Most pharmacists (80%) were willing to implement PharmFIT. The most common reasons for unwillingness were that results needed to be reported to the patients' primary care providers (52%), that appropriate training in delivering colorectal cancer screening be provided (48%), and that care coordination with primary care providers be clear (46%). Perceived complexity of the intervention decreased as years in practice increased [β = 0.013; 95% confidence interval (CI), 0.01-0.02] and as the level of knowledge about colorectal cancer screening increased (β = 0.085; 95% CI, 0.01-0.16). Respondents' willingness to implement PharmFIT increased as perceived complexity decreased (OR = 5.68; 95% CI, 3.96-8.15). AB - Most community pharmacists in the United States would be willing to integrate PharmFIT into their current workflows. Training in how to deliver fecal immunochemical testing and preparation for the coordination of test results and follow-up care should be completed prior to implementing PharmFIT. AB - Community pharmacies are a viable venue for delivering colorectal cancer screening. AB - Author manuscript AN - cdc:261219 C4 - PMC12414247 DO - https://doi.org/10.1158/1055-9965.EPI-25-0275 IS - 10 J2 - Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology KW - Attitude of Health Personnel KW - Surveys and Questionnaires KW - Female KW - Colorectal Neoplasms KW - Pharmacists KW - Community Pharmacy Services KW - Male KW - Aged KW - Middle Aged KW - Humans KW - Early Detection of Cancer KW - Adult KW - Pharmacy KW - Colorectal cancer screening KW - CRC screening KW - fecal immunochemical test KW - Cancer prevention KW - Preventive medicine KW - Diffusion of innovation KW - Humans KW - Colorectal Neoplasms KW - Pharmacists KW - Male KW - Female KW - Early Detection of Cancer KW - Middle Aged KW - Surveys and Questionnaires KW - Aged KW - Adult KW - Community Pharmacy Services KW - Attitude of Health Personnel LA - eng PY - 2025 T2 - Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology T2 - Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 2025, v. 34, no. 10 TI - It is a Good Idea, But Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening. VL - 34 UR - https://stacks.cdc.gov/view/cdc/261219 ER -

Previous Page Previous

1301 - 1320 / 1994

Next Page Next

Found an issue?

Send us an email at: publishinghd@cdc.gov